University of New Mexico

UNM Digital Repository
Biomedical Sciences ETDs

Electronic Theses and Dissertations

7-1-2015

Inhibition of Virulence as Treatment Strategies for
Staphylococcus aureus Infection
Seth Michael Daly

Follow this and additional works at: https://digitalrepository.unm.edu/biom_etds
Recommended Citation
Daly, Seth Michael. "Inhibition of Virulence as Treatment Strategies for Staphylococcus aureus Infection." (2015).
https://digitalrepository.unm.edu/biom_etds/121

This Dissertation is brought to you for free and open access by the Electronic Theses and Dissertations at UNM Digital Repository. It has been
accepted for inclusion in Biomedical Sciences ETDs by an authorized administrator of UNM Digital Repository. For more information, please contact
disc@unm.edu.

Seth Michael Daly
Candidate

Biomedical Sciences
Department

This dissertation is approved, and it is acceptable in quality and form for publication:
Approved by the Dissertation Committee:

Pamela R. Hall, Chairperson

Graham S. Timmins

David Peabody

Bryce Chackerian

i

INHIBITION OF VIRULENCE AS TREATMENT STRATEGIES FOR
STAPHYLOCOCCUS AUREUS INFECTION

BY

SETH MICHAEL DALY
B.S., Biology, New Mexico Institute of Mining and Technology, 2007
M.S., Biology, New Mexico Institute of Mining and Technology, 2010

DISSERTATION
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Doctor of Philosophy
Biomedical Sciences
The University of New Mexico
Albuquerque, New Mexico

July 2015
Copyright © Seth M. Daly, Albuquerque, New Mexico 2015

ii

DEDICATION
To everyone who kept me hearty and hale through a decade of college.

iii

ACKNOWLEDGEMENTS
I would like to first thank my mentor Dr. Pamela Hall. It has been enjoyable to work in a
laboratory where I can laugh with her and my co-workers, especially during our many
mistakes. Although I am her first graduate student, her mentorship has been nothing less
than stellar and her championing of me and my work has been incrediby appreciated. It
has been a pleasure. Finding someone to fill your boots will be tough indeed.
I would also like to thank my undergraduate and Master’s degree advisor Dr.
Snezna Rogelj. She pushed me from the start and made me promise that I would earn my
doctorate. I also want to thank my Master’s committee, Drs. Thomas Kieft and Igor
Magedov, and my Doctoral committee, Drs. Graham Timmins, Dave Peabody, and Bryce
Chackerian, for their fantastic advice and support.
A really huge thank you goes out to all the graduate students, post-docs, and
technical staff I have worked with. Going through this with camaraderie and support both
mentally and experimentally was phenomenal. Additionally, a big thank you goes to all
the administrative staff within the BSGP, Pharmaceutical Sciences, and IDIP. You keep
us all up to date and in the money with a mountain of paperwork, which is a huge
undertaking, thank you. I was also extremely fortunate to receive a T32 pre-doctoral
fellowship from the IDIP training program. I would like to thank all the mentors, first for
my acceptance, but also for their input and guidance during my training.
I gratefully acknowledge the intellectual and experimental contributions of Dr.
Hattie Gresham and members of her laboratory, specifically Erin Sully and Susan
Alexander, who made this project possible. Dr. Gresham's group sought and identified
the first small molecule inhibitor of S. aureus quorum sensing, savirin, with in vivo
activity. During this pioneering work, they established many of the models and protocols
essential to my work with the natural product inhibitor of quorum sensing, OHM. I would
also like to thank the laboratories of our collaborators, Drs. Alex Horswill, Nick Oberlies,
Nadja Cech and Jon Femling.
Lastly I want to thank all of my friends and family. To all the Dalys, Dummers,
and Arrossas, thank you for being a constant source of love, encouragement, and humor.
To my lovely lady, Ashley Arrossa, thank you for putting up with all the grumpiness and
complaints through two graduate degrees. Thank you for supporting me with patience,
love and money…and hopefully now I can contribute to the last. I love you, balloons. To
all my friends, keeping me busy and happy outside of work has been stressful, but it was
also absolutely necessary for my mental well being and ultimate success, thank you.
A final thank you to everyone again, including anyone I may have missed, your
support made me successful, and I am grateful.

iv

INHBITITION OF VIRULENCE AS TREATMENT STRATEGIES FOR
STAPHYLOCOCCUS AUREUS INFECTION
BY
SETH MICHAEL DALY
B.S., Biology, New Mexico Institute of Mining and Technology, 2007
M.S., Biology, New Mexico Institute of Mining and Technology, 2010
Ph.D., Biomedical Sciences, University of New Mexico, 2015

ABSTRACT

Staphylococcus aureus is a global health threat due to its ability to cause significant
morbidity and mortality and the exceptional capacity to acquire antibiotic resistance. One
method to combat antibiotic resistance, proposed by the NIAID, is anti-virulence
strategies focused on bacterial disarmament. S. aureus regulates over 200 virulence
factors with the accessory gene regulator (agr) operon, which encodes a quorum sensing
(QS) system, and many of the agr-regulated virulence factors are required for invasive
infection. Therefore, we hypothesized that bacterial disarmament through the inhibition
of agr quorum sensing will both complement immune function and mitigate the severity
of S. aureus infection. First, in Chapter 2, we report the development and demonstrate
the efficacy of the first active vaccine targeting the secreted signal of the agr system. The
use of stable peptide mimotopes displayed with high valency on a virus-like particle
proved successful in limiting agr-dependent pathogenesis in vivo, a significant advance in
the field. Second, in Chapter 3, we utilize a novel natural product inhibitor of AgrA, ωhydroxyemodin, to demonstrate that bacterial disarmament can both limit S. aureus
pathogenesis and support host innate defense resulting in increased bacterial clearance.
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This is the first small molecule S. aureus QS inhibitor to demonstrate in vivo efficacy and
a definitive mechanism of action. Both of the approaches demonstrate that inhibitors of
QS would be efficacious as treatments to limit skin infections. Understanding the role of
agr in other disease states such as pneumonia and bacteremia would enhance the clinical
utility. Likewise, it will be essential to determine if QS inhibitors can function as
adjunctive therapy to extend the clinical lifetime of current antibiotics. Inhibition of QS
alone is not going to solve the antibiotic resistance crisis, but it is another tool that can be
used to fight resistance.
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CHAPTER 1: Introduction and Background

S

taphylococcus aureus, which roughly translates to ‘bunch of grapes’ for the
characteristic purple cocci clusters following Gram stain and ‘golden’ for the color

of colonies on solid media, was first described over a hundred years ago (reviewed in
(1)). In the pre-antibiotic era, S. aureus was attributed mortality rates exceeding 80% (2).

The advent of penicillin in the 1940s dawned the ‘Golden Age’ of antibiotics, but within
two years resistance developed and to date less than 5% of S. aureus are sensitive to
penicillin (3). The introduction of methicillin in 1961, which was designed to target
penicillin-resistant strains, was met only a few years later with resistant strains termed
methicillin-resistant S. aureus or MRSA (3, 4). Resistance to a wide range of antibiotics
has continued to develop following introduction to the clinic, including to the gold
standard of care vancomycin (4). In 2013, the Centers for Disease Control and Prevention
(CDC) released an antibiotic threats document that named MRSA a ‘Serious Threat’ level
organism (5). In this document the CDC attributed over 11,000 deaths to MRSA in 2011,
and it is important to note this number does not address deaths due to methicillinsensitive (MSSA) infections (5). The continual rise of resistance, in all bacteria, coupled
with the dearth of novel pharmaceuticals, is a crisis that has been approached at national
levels with initiatives for antibiotic discovery, such as the British “Antibiotic Action” and
the American “10 x ’20” programs (6, 7). However, non-traditional methods for
addressing the resistance threat are gaining traction due to the seemingly inevitable
development of resistance anticipated for even future antibacterial agents (8, 9). These
non-traditional methods include harnessing and enhancing host immune responses and
inhibition of bacterial virulence (8, 9). Herein, two approaches that fall into these non-
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traditional methods for combating S. aureus infection will be described following a
review of the relevant literature.

Disease severity and risk factors
S. aureus is a human commensal, colonizing the anterior nares of ~20% of people
persistently and 60% transiently (10). Importantly, this commensal has the capacity to
become a significant pathogen, and nasal carriage increases the risk of autoinfection (11).
Skin and skin structure infections (SSSIs) represent the major burden of infection caused
by S. aureus, accounting for about 90% of all infections (12). In a study of SSSIs
presenting to emergency departments in the United States, 76% were caused by S. aureus
and 59% of those infections were due to MRSA strains (13). Additionally, the SENTRY
Antimicrobial Surveillance Program found S. aureus to be the leading etiological agent of
SSSIs in North America, Latin America, and Europe (14, 15). SSSIs can range from
simple furuncles to life-threatening systemic infections such as necrotizing fasciitis (14,
16). Finally, recent or concurrent SSSI is a risk factor for developing blood stream
infection (17). Although SSSI represent the majority, other disease states are also
associated with this pathogen, such as endocarditis, bone and joint infections, pneumonia,
device related infections, and bacteremia (12). Even with current therapeutics and best
practices, mortality rates for bacteremia are estimated at 10-40% (3, 18).
Populations susceptible to S. aureus infections can be grouped into either genetic
or non-genetic risk factors. Genetic predispositions include neutrophil disorders such as:
Job’s syndrome where mutations in signal transducer and activator of transcription 3
(STAT3), a transcription factor important for immune signaling, lead to hyper-IgE and
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dysfunctional TH17 responses (19); Chediak-Higashi syndrome where mutations in the
lysosomal trafficking regulator (LYST), leads to lysosomal transport errors (20); and
chronic granulomatous disease which is due to a defect in the enzyme NADPH oxidase,
resulting in a lack of oxidative killing in phagosomes (21). Other genetic predispositions
include defects in toll-like receptor 2 (TLR2), a bacterial pattern recognition receptor
(22), and complement deficiencies (23). Non-genetic risk factors include: hospitalization,
contact sports, imprisonment, military service, diabetes, intravenous access (illicit and
licit), surgical intervention, immunosuppression (chemical and infections) and old age (3,
14, 24–27). Additionally, although MRSA was previously thought of primarily as a
nosocomial, or healthcare associated infection (HA-MRSA), in the 1990s the
epidemiology shifted to include infections associated with onset in the community (CAMRSA) in otherwise healthy persons (reviewed in (28)). Interestingly, CA-MRSA are
paradoxically more susceptible to antibiotics but more virulent than HA-MRSA (28). Not
only is MRSA resistant to a wider range of antibacterial agents compared to MSSA, it is
also associated with increased mortality, length of hospital stay, increased healthcare
cost, and overall increased economic burden (29–32).

Current and Proposed Therapy
Although S. aureus is becoming increasingly resistant to antibiotics, some efficacious
antibiotics are still available and their use depends on the severity infection.
Recommended treatment of simple furuncles and abscesses is incision and drainage with
concomitant culture and sensitivity testing (16). SSSIs of increased complexity requires
the use of empiric and then defined antibiotic treatment following susceptibility testing
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(16). MSSA can be treated with nafcillin, oxacillin, dicloxacillin, cefazolin, and
cephalexin while vancomycin, dalbavancin, oritavancin, linezolid, daptomycin,
ceftaroline, clindamycin, doxycycline, and trimethoprim-sulfamethoxazole are also
effective against MRSA (16). Although there are still clinically useful therapeutics
available for the treatment of MRSA, many are administered by intravenous route only,
have significant adverse effects, and are cost prohibitive (33). Additionally, the continual
increase in minimal inhibitory concentration (MIC) values and emergence of
vancomycin-intermediate (VISA) and vancomycin-resistant strains (VRSA) will require
novel treatments (33, 34). Although there are a few antibiotics in development for the
treatment of S. aureus infections (33, 35), antibiotic development as a whole is declining,
resistance is rising, and clinical needs are not wholly met (8, 35). To address this rise in
resistance, the CDC outlined four stratagems to prevent resistance in their 2013 Drug
Resistance Threat Report (5): (a) prevention of infections, which precludes the use of
antibiotics, (b) tracking of infections, to assess risk factors and put control programs in
place, (c) antibiotic stewardship, to control and educate about the proper use of
antibiotics, and (d) developing novel antibiotics and tests to track resistance. In addition
to the CDC recommendations, the National Institute of Allergy and Infectious Diseases
(NIAID) has proposed the following non-traditional approaches to combat antimicrobial
resistance (9):
•

Systems Biology and Antibacterial Resistance

•

Harnessing the Immune System to Combat Bacterial Infections

•

Disarm, But Leave Unharmed: Exploring Anti-Virulence Strategies

•

Synthetic Microbiota: An Ecobiological Approach
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•

Less is Better: Diagnostics to Guide Use of Narrow-Spectrum Therapeutics

•

Exploiting Natural Predators: the Specificity of Phage Therapy

•

Teaching Old Drugs New Tricks: Extending the Clinical Utility of Antibacterial
Drugs

The body of work reported in this dissertation focuses on two not mutually exclusive
strategies, ‘anti-virulence’ and ‘harnessing the immune system,’ that can be used to
combat S. aureus infections.

S. aureus virulence regulation
Bacterial virulence is the capacity of an organism to cause disease, so inhibition of
virulence, as proposed by NIAID, seeks to prevent the pathogenesis of infection. The
expression of virulence factors is energetically expensive for an individual bacterium, as
such many bacteria have evolved mechanisms that allow the ‘switching’ from avirulent to
virulent phenotypes (36, 37). One such mechanism is quorum sensing (QS), which is a
bacterial density-dependent cell to cell communication system (reviewed in (36)). In
brief, QS functions through a secreted messenger (autoinducer, AI) that acts as both an
autocrine and paracrine signal (36). At low cell density the AI is not at sufficient
concentration to activate the regulatory QS circuit. As bacterial density increases, the AI
concentration hits a critical concentration, positively regulating the QS circuit (feedforward) while also activating the QS regulon (36). Many Gram positive and Gram
negative organisms use QS to coordinate virulence gene expression (36); therefore,
inhibition of QS represents an excellent target for anti-virulence strategies as requested
by the NIAID.
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S. aureus utilizes a two-component QS system consisting of a peptide AI binding
to a membrane bound receptor histidine-kinase, which in turn activates a cytoplasmic
response regulator (36, 38). The accessory gene regulator (agr) originally identified in
1986 (39), is a Staphylococcal QS operon controlling the switch between colonizing
(adherent) and invasive (virulent) phenotypes. (reviewed in (38)). As shown in Figure
1.A, the agr locus contains two divergent promoters P2 and P3, which encode the four
gene QS operon, agrBDCA, and the effector molecule RNAIII, respectively. Briefly,
AgrB is membrane endopeptidase that cleaves and cyclizes the propeptide AgrD, and
transports the mature autoinducing peptide (AIP) into the extracellular environment. The
mature thiolactone cyclized AIP can then bind the cognate receptor histidine-kinase
AgrC, resulting in activation (phosphorylation). Active AgrC phosphorylates the
response regulator AgrA, which can then bind and initiate transcription at the P2 and P3
promoters as well as the phenol soluble modulin α and β (psmα, psmβ) promoters. P2
transcription results in the feed-forward activation in the agrBDCA operon, resulting in
population synchrony (36). Transcription of P3 results in the effector molecule, RNAIII,
which is the master regulator of virulence. RNAIII post-transcriptionally regulates the
agr regulon by binding to mRNAs, masking or unmasking Shine-Dalgarno sequences,
and thus preventing or enabling translation, respectively.
Evolutionary variation has resulted in four agr alleles (agr-I, -II, -III, and -IV)
among S. aureus. Strains representing the four alleles differ in the composition of the AIP
molecule (AIP1-4), both in amino acid composition and length (Figure 1.B). Due to the
differences in the AIP messenger, both the C-terminus of AgrB and N-terminus of AgrC
vary to account for processing and recognition, respectively, of the cognate AIP. The
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response regulator, AgrA, is conserved across all four agr types. Interestingly, due to the
variation in AIP, cross-strain interference occurs whereby each strain’s AIP can inhibit
the non-cognate AgrC. The exception is between agr-I and agr-IV, presumably because
the AIPs only differ in a single amino acid. Not surprisingly, because the agr system is
conserved across Staphylococci, in vitro inter-genus and intra-species agr interference
has been reported (40–43).
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Figure 1.1 - Schematic of the S. aureus accessory gene regulator quorum-sensing
system. (A) The agr P2 promoter drives the expression of the four genes of the operon
agrBDCA. AgrD is a propeptide that is cyclized to form autoinducing peptide (AIP) and
secreted via AgrB. AIPs from the four agr alleles vary in length from seven to nine
amino acids, but all contain a five-membered thiolactone ring. Secreted AIP binds to its
cognate receptor AgrC, activating its histidine kinase function leading to the
phosphorylation of AgrA. AgrA binds to the divergent promoters P2 and P3 as well as
the promoters for the transcription of the phenol-soluble modulin (PSM) toxins. P2 drives
a positive-feedback loop resulting in the upregulation of the agr operon, whereas P3
drives the transcription of the effector molecule RNAIII. RNAIII leads to the
upregulation of virulence factors that contribute to invasive infection. (B) Sequences of
the AIP1-4 molecules of the respective agr types I-IV.
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The agr system regulates expression of more than 200 virulence genes (44). In
general, agr activation results in the upregulation of secreted proteins that aid in tissue
invasion, while down regulating membrane proteins that are essential for adherence,
colonization, and biofilm formation (38, 45). Virulence factors positively regulated by
agr in an RNAIII-dependent manner include: (a) membrane-active toxins, exemplified by
the heptameric pore forming α-hemolysin (Hla) (46), but also including γ-, β-, and δhemolysin and the two-component leukocidins (D/E, S/F, and G/H), (b) tissue degrading
proteases and lipase, (c) the ROS scavenging pigment staphyloxanthin (which also lends
the characteristic gold colony color) and (d) numerous superantigens which can cause
sepsis and adaptive immune cell death (38). Virulence factors negatively regulated by agr
include: (a) fibronectin binding proteins A and B, (b) the immunoglobulin binding
protein A, and (c) coagulase (38). In addition to the RNAIII regulated proteins, AgrA
directly activates the transcription of the phenol soluble modulins encoded by psmα and
psmβ leading to the translation of six small amphipathic proteins involved in host cell
chemotaxis and membrane damage (PSMα1-4 and PSMβ1-2) (47). Together, these and
other virulence factors contribute to invasive infection through a variety of functions.
Many of the virulence factor effects are concentration dependent, including direct killing
of immune cells, prevention or activation of chemotaxis, prevention of phagocytosis,
intracellular survival and lysosomal escape after phagocytosis, and dysregulation of
immune signaling (48–51).
The rising antibiotic resistance of S. aureus coupled with the large burden of
disease requires novel approaches to combating this pathogen. Due to the pleiotropic
effects on virulence, QS inhibition of S. aureus has been suggested as a target for clinical
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intervention (36, 52–54). There are several lines of support for this stratagem. First,
infection with agr deletion mutants drastically attenuates the severity of multiple disease
states (44, 55, 56). Second, innate immunity has evolved responses that inhibit QS such
as ROS inactivation of the AIP molecule (57), binding and subsequent sequestration of
AIP by lipoproteins (58, 59), and QS inhibition by hemoglobin (60). Third, because
inhibitors of quorum sensing do not have direct bactericidal activity they have been
posited not to drive resistance. In support of this hypothesis, it was recently demonstrated
that S. aureus resistance to a classical antibiotic developed readily in vitro and in vivo but
agr remained susceptible to small molecule inhibition (55). Therefore, inhibition of S.
aureus QS may be a clinically viable option for prevention and/or treatment of S. aureus
infection.

Progress towards a S. aureus vaccine
Vaccination is a cornerstone of modern medicine that has resulted in the eradication of
smallpox, the drastic reduction of polio, and immense reduction of death due to multiple
bacterial and viral infections. Importantly, vaccines directed at virulence factors such as
Haemophilus influenzae B (HiB) capsule (61), and the secreted bacterial diphtheria,
tetanus and pertussis toxins (DTaP) have been highly successful (62). It would seem
straightforward, therefore, that since S. aureus can be encapsulated and produces toxins, a
similar vaccination strategy would be effective. However, to date, vaccine approaches
which are effective against other pathogens have failed against S. aureus.
The failure of conventional vaccine approaches to protect against, S. aureus
infection may be due to its status as a common commensal. S. aureus colonization
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happens very early in life leading to a large number of antibodies against many
Staphylococcal antigens in sera of adults (63). Sadly, these natural antibodies do not
protect from infection and recurrent infections are common even with increased
anamnestic response post-infection (63–65). Additionally, patients with B cell or
antibody deficiencies are not at increased risk for infection (26), calling into question the
potential efficacy of B-cell targeted vaccination for S. aureus infection. Conversely,
while colonized patients are more likely to be auto-infected, they are also less likely to
succumb to infection (11, 66), and the number of S. aureus virulence factors dedicated to
humoral evasion suggest that antibody responses are important (63). Interest in a
Staphylococcal vaccine is not a modern medical phenomenon. In 1930, then the preantibiotic era, Weise reported some clinical success using purified toxin (now known to
be Hla) as an active vaccination for recurrent furunculosis (67). However, now almost a
century later, there is still no licensed S. aureus vaccine despite a large volume of basic
science and clinical vaccine trials.
To illustrate the significant amount of work already completed clinically, Table
1.1 is a compilation of the completed and active efficacy trials (phase II and III),
accessible on clinicaltrials.gov, to treat or prevent S. aureus disease. Most of the studies
have been completed as per clinicaltrials.gov (see NTC# identifiers), but no results are
posted or available in the primary literature. The majority of trials have been formulated
with one or two surface-associated antigens. These antigens include S. aureus capsule 5
and 8, the cell wall-associated lipotechoic acid (LTA) and poly-N-acetyl glucosamine
(PNAG), and the binding factors: clumping factor A (ClfA), iron-regulated surface
determinant B (IsdB), and serine-aspartate repeat G (SdrG). The goal of antibodies
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against these targets, generated actively through immunization or passively by injection,
has been opsonization of S. aureus leading to complement or phagocyte-mediated killing.
Additionally, there are several trials addressing the efficacy of antibodies directed at
preventing the action of secreted toxins such as Hla and Panton-Valentine leukocidin. Of
the seven completed studies with published results (Table 1.1), five showed no protection
compared to placebo (68–73), with one actually showing increased mortality in
vaccinated patients upon infection (72). Of the remaining two completed studies, one
demonstrated a decrease in length of hospital stay but no reduction in bacteremic
mortality (74). The other study demonstrated protection of hemodialysis patients from
bacteremia up to ~40 weeks, but there was no significant protection at the pre-identified
endpoint of 52 weeks (75).
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Table 1.1 – Completed active and passive vaccines targeting S. aureus
Identifier

Target(s)a

Phase

Patients/Disease

Result(s)

Authorb

II

Adults with bacteremia
(Std. Rx + pAb or placebo)

No mortality difference vs. placebo
Significantly reduced LOS

(74)

II

Preventing nosocomial infection in neonates (pAb vs. placebo)

No difference vs. placebo

(68)

Passive

Altastaph

CP5, CP8

Aurexis
(Tefibazumab)

ClfA

II

Adults with bacteremia
(mAb vs. placebo)

No difference vs. placebo

(69)

Aurograb

ABC
transporter

II

Outcome of infected patients on vancomycin (Fab vs. placebo)

Completed, no results published

NCT00217841

KBSA301

Hla

II

Determine PK/PD, outcome of current pneumonia patients (mAb vs. placebo)

Recruiting as of April 2012

NCT01589185

SAR279356

PNAG

II

Determine PK/PD, prevention of infection of ventilator patients (mAb vs.
placebo)

Terminated, no results posted

NCT01389700

514G3

Not disclosed

II

Determine PK, outcome of current bacteremia patients (Proprietary Ab vs.
placebo vs. Std. Rx)

Starting April 2015

NCT02357966

Pagimaximab

LTA

II / III

Preventing nosocomial infection in neonates (mAb vs. placebo)

No difference vs. placebo

(70, 73)

Veronate

ClfA, SdrG

III

Preventing nosocomial infection in neonates (pAb vs. placebo)

No difference vs. placebo

(71)

a

Commas indicate combined antigens. bIf no peer-reviewed results are published the clinicaltrials.gov identifier is listed.

Abbreviations: ABC Transporter - ATP-binding cassette transporter; ClfA - clumping factor A; CP5, CP8 - capsule type 5, 8; Fab - fragment antigen-binding; Hla - alpha-hemolysin; LOS - length
of stay; LTA - lipotechoic acid; mAb - monoclonal antibody; PD - pharmacodynamics; PK - pharmacokinetics ; pAb - polyclonal antibody; PNAG - poly-N-acetyl glucosamine; SdrG - serineaspartate repeat G; Std. Rx - Standard Treatment
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Table 1.1 – Continued.
Target(s)a

Phase

Patients/Diseaseb

Result(s)

Authorc

SA3Ag; SA4Ag

CP5-DT, CP8DT, ClfA;
+MntC

II

Immunogenicity

Completed, no results published

NCT01643941

SA4Ag

CP5-DT, CP8DT, ClfA, MntC

II

Preventing postoperative infection after spinal surgery

Starting June 2015

NCT02388165

Hla

II

Immunogenicity

Completed, no results published

NCT01011335

LukS-PV

II

Immunogenicity

Completed, no results published

NCT01011335

Hla, LukS-PV

II

Immunogenicity

Completed, no results published

NCT01011335

III

Preventing bacteremia in hemodialysis patients

Protection to about 40 weeks (Booster study
demonstrated increased Ab levels)

(75, 76)

III

Immunogenicity in cardiovascular surgery patients

Completed, no results published

NCT00211913

III

Immunogenicity in orthopedic implant patients

Completed, no results published

NCT00211926

Preventing infection in surgical patients

Terminated. No difference vs. placebo, but vaccinated
had elevated mortality risk

(72)

Identifier
Active

Toxoids' USUHS

StaphVax

V710

CP5-exoA, CP8exoA

IsdB

III

a
Hyphenation represents conjugation of antigens, while commas indicate combined antigens. bAll vaccinations are compared to placebo controls. cIf no peer-reviewed results are published the
clinicaltrials.gov identifier is listed.

Abbreviations: Ab - antibody; ClfA - clumping factor A; CP5, CP8 - capsule type 5, 8; DT - diphtheria toxin; exoA - exotoxin A; Hla - alpha-hemolysin; IsdB - iron-regulated surface determinant B;
LukS-PV - Panton-Valentine leukocidin subunit S; MntC - manganese transport protein C; USUHS - Uniformed Services University of the Health Sciences

14

There have been numerous reviews addressing the potential reasons for S. aureus
clinical vaccine failures (reviewed most recently in (77, 78)). Some of the potential
reasons for failure include, but are not limited to: (a) inappropriate choice of clinical trial
populations and endpoints (79–81); (b) widespread S. aureus colonization, which may
suggest immune tolerance, and the numerous and redundant immune circumvention
mechanisms utilized by this pathogen (49, 66, 82, 83); (c) animal models, especially
mice, have proven to be poor predictors of vaccine efficacy in humans, and because
human correlates of protection are not well known, developing models is difficult (84,
85); (d) the variability of S. aureus antigen expression, due both to strain and growthphase/QS control, suggests that single antigens may not be effective (77, 78, 86); and (e)
cell-mediated immunity, especially TH17/IL-17 responses as opposed to opsonizing
antibodies, may be required for human protection (77, 78, 86). As it becomes more
apparent that cellular immunity is an important protective correlate (87), vaccines which
address this need should be in the forefront.
More recent clinical trials have begun to address some of the aforementioned
vaccine issues, including the use of multiple-antigens and vaccines that drive cellmediated TH17/IL-17 responses. For example, Pfizer is developing three- and fourantigen vaccines (phase II complete, Table 1.1), GSK is pursuing a four antigen vaccine
comprised of CP5-TT, CP8-TT, Hla, and ClfA (phase I complete, NCT01160172), and
Vaccine Research International has completed a phase I trial of a trivalent vaccine
containing collagen binding protein (Can), extracellular adherence protein (Eap) and Clf
(http://www.vri.org.uk). Additionally, there are two completed phase I trials of NDV-3,
which is based on Candidal agglutinin-like sequence 3 protein (Als3) that shares
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homology with Staphylococcal adhesins (88), and in mice protection is mediated by
TH17/IL-17 responses (88–90).
To demonstrate the potential for inhibiting S. aureus QS as a vaccination strategy,
Table 1.2 is a list of vaccines tested in vivo that contain at least one agr-regulated
antigen. Table 1.2 was generated by searching the PubMed (www-ncbi-nlm-nih.gov)
database with the two searches ‘aureus and vacc*’ and ‘aureus and immunother*’ from
2005 through 2015, which resulted in 935 publications (* utilizes lemmatization [e.g. –
vacc* would search for vaccine, vaccination, and vaccinology, etc.]). These results were
then filtered for vaccines utilizing at least one agr-regulated virulence factor, and if
literature on the same vaccine formulation was reported more than once, the seminal
paper was identified. Due to conflicting reports, vaccines involving the RNAIIIactivating protein (RAP) or related proteins were not included (91, 92). Of note, besides
the intended targets, this search yielded three additional interest areas with significant
literature: (a) epidemiology and economic analyses to identify at risk populations and the
benefits of vaccination, (b) literature reviews addressing the failures, potential reasons for
failure and the urgent clinical need for an S. aureus vaccine, and (c) a large volume of
literature looking for efficacious zoonotic vaccines, mostly for bovine mastitis. Since the
table was designed to demonstrate the large amount of agr-regulated antigens that are
protective in vivo, it does not list antigen modification (e.g. inactivating mutations),
conjugation to carriers, or adjuvants, even though all are important in vaccine formulation
and ultimate efficacy.
In addition to identifying novel targets with protective efficacy, many of the
studies listed in Table 1.2 seek to address, in animals, the shortcomings identified in
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human trials. First, 12 of the 25 studies (48%) contain multiple antigens, addressing the
variability of antigen expression due to disease, growth-phase, and strain. Many
combinations of agr- and non-agr-regulated antigens have been conjugated or formulated
together with in vivo success (93–95). One study even combined two antigens oppositely
regulated by agr, which may also drive protection at different agr activation states (94).
Second, multiple investigators have assessed vaccination with small linear epitopes,
domains, or discontiguous epitopes of S. aureus virulence factors that are protective (96–
98). Additionally, Pozzi et al. demonstrated that conjugating protein antigens to nonprotein antigens can overcome antibody interference following vaccination with multiple
antigens (94). These studies are essential to understanding the antigen requirements for
the formulation of successful multivalent vaccines. Third, many of the vaccines assessed
efficacy in multiple disease models (94–96, 99–103), immune deficient states (99, 104),
and in animals other than mice (93, 105–107), although mouse models are predominant.
These are all an effort to identify protective correlates for different human disease states
and host-susceptibilities. Fourth, it has been suggested that anti-toxin antibodies may be
less desirable than opsonizing antibodies that lead to S. aureus killing, because toxins are
usually expressed after initiation of infection (79), although their use has also been
championed (108). The large number of successful anti-toxin strategies assessed in
animals (Table 1.2), especially by Spaulding et al. who demonstrated that a large cocktail
of toxin antigens alone is protective(105), suggests that anti-toxin approaches are
effective. Even more encouragingly, several of the toxin only approaches actually
showed reductions in CFUs in vivo (96, 101, 102, 105, 109), which is secondary to their
neutralizing activity. This is an example of the not mutually exclusive strategy outlined
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by the NIAID, where ‘anti-virulence’ leads to ‘harnessing the immune system.’
Ultimately, the two human clinical anti-toxin vaccine trials actively being pursued (Table
1.1) should elucidate the contribution of toxin components to a successful clinical
vaccine. Fourth, Bagnoli et al. and Yeaman et al. are assessing antigens that drive
TH17/IL-17 responses (95, 110), which furthers the understanding of cell-mediated
immunity in S. aureus vaccination. Fifth, two studies have demonstrated that antibody
responses to the immunoglobulin-binding protein A (SpA) are protective in animal
models (99, 111), suggesting that antibodies raised to immunoevasive antigens may be
effective. Lastly, and most relevant to the work herein, Park et al. demonstrated the
efficacy of targeting the agr quorum sensing operon to globally downregulate virulence
in multiple disease models of S. aureus infection (103).
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Table 1.2 – Animal model tested S. aureus vaccines containing at least one agr-regulated antigen (2005-2015).

Year

Target(s)a and
agr (+/-)b

Strategy

Model

Major in vivo Positive Results

Author

2015

Csa1A, EsxA+, EsxB, FhuD2,
Hla+

Active

Ms bacteremia; SSSI; peritonitis,
pneumonia

↑Survival and ↓CFU; ↓CFU and abscesses; ↑survival; ↑survival

(95)

2015
2015

Hla+
SpA-

Active, Passive Rb
Passive Ms

Ms SSSI
Ms SSSI, bacteremia

↓Dermonecrosis and bacterial luminescence
↑Survival; ↑Survival

(98)
(99)

2014

AIP4+

Active

Ms SSSI

↓Abscess, ulcer, IL-1β and Hla

(112)

2014

Als3-

Active

Ms SSSI

↓Dermonecrosis, CFU and bacterial luminescence

(110)

2014

ClfA-, FnBPB-, SdrD-, SpA-

Active

Luekopenic Ms bacteremia

↑Survival and ↓CFU

(104)

2014

Combinations of: TSST-1+,
SEB+, SEC+, SEl-X, Hla+,
Hlb+, Hld+

Active, passive Rb

Rb pneumonia

↑Survival and ↓CFU

(105)

2014

CP5+-Hla+

Active, passive Rb

Ms bacteremia, pneumonia

↑Survival and ↓CFU, weight loss; ↑Survival and ↓CFU

(100)

2014

CP5+-TT or CP8+-TT, Hla+

Active

Rt osteomyelitis

↓CFU and osteomyelitis pathology

(107)

2014

EpiP+

Active

Ms peritonitis

↑Survival

(113)

2014

FnBPA-

Active

Ms bacteremia

↑Survival and ↓CFU

(114)

a

Hyphenation of target antigens indicates conjugation, while commas indicate combined antigens. bSuperscript +/- denotes positive or negative agr regulation, respectively.

Abbreviations: AIP4 - autoinducing peptide 4; Als3 - agglutinin-like sequence 3 protein; CFU - colony forming unit; ClfA - clumping factor A; CP5, CP8 - capsule type 5, 8; Csa1A - conserved
staphylococcal antigen 1A; EpiP - epidermin leader peptide processing serine protease; EsxA, EsXB - ess extracellular A, B; FhuD2 - ferrix hydroxamate-binding lipoprotein; FnBP A, B fibronectin binding protein A, B ; Hla, Hlb, Hld - alpha-, beta-, gamma-hemolysin; Ms - mouse; Rb - rabbit; Rt - rat; SdrD - serine-aspartate repeat D; SEB, SEC - staphylococcal enterotoxin B, C;
SEl-X - staphylococcal enterotoxin-like X; SSSI- skin and skin structure infection; TSST-1 - toxic shock syndrome toxin-1; TT - tetanus toxin
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Table 1.2 – Continued.

Year

Target(s)a and
agr (+/-)b

Strategy

Model

Major in vivo Positive Results

2013

Hla+

Active

Ms SSSI (ear), bacteremia, implant

↓Dermonecrosis and ↓CFU; ↓CFU; no protection

(101)

2013

IsdB+-Hla+

Active

Ms bacteremia

↑Survival and ↓CFU

(115)

LukS+

Active, passive

Ms bacteremia

↑Survival and ↓CFU in multiple organs

LukF+

Active

Ms bacteremia

↑Survival and ↓CFU in multiple organs

LukF+, LukS+

Active

Ms bacteremia

↑Survival (best) and ↓CFU in multiple organs

2013

SEB+

Active, passive Ms

Ms bacteremia. SSSI

↑Survival; ↓Abscess, dermonecrosis and CFU

(102)

2012

ClfA--PNAG

Passive Gt

Ms bacteremia

↓CFU

(93)

Coa-/+

Active, passive Rb

Ms bacteremia

↑Survival

vWbp

Active, passive Rb

Ms bacteremia

↑Survival

Coa-/+, vWbp

Active

Ms bacteremia

↑Survival

Glc-Hla+

Passive Rb

Ms pneumonia; SSSI

↑Survival and ↓CFU; ↓CFU

CP5+-ClfB-

Passive Rb

Ms SSSI; colonization

↓CFU; ↓CFU

CP8+-IsdB+

Passive Rb

Ms SSSI

↓CFU

Passive Rb

Ms SSSI

↓CFU

Active, passive Rb

Ms bacteremia, pneumonia

↑Survival and ↓CFU, ↑Survival and ↓CFU

2013

2012

2012

+

+

-

+

Glc-Hla , CP5 -ClfB , CP8 IsdB+
2012

a

Hla

+

Author

(109)

(97)

(94)

(96)

Hyphenation of target antigens indicates conjugation, while commas indicate combined antigens. bSuperscript +/- denotes positive or negative agr regulation, respectively.

Abbreviations: CFU - colony forming unit; ClfA, B - clumping factor A, B; Coa - coagulase; CP5, CP8 - capsule type 5, 8; Glc - PNAG fragment; Gt - goat; Hla - alpha-hemolysin; IsdB - ironregulated surface determinant B; LukS, LukF - Panton-Valentine leukocidin subunits; Ms - mouse; PNAG - poly-N-acetyl glucosamine; Rb - rabbit; SEB - staphylococcal enterotoxin B; SSSI- skin
and skin structure infection; vWbp - von Willebrand factor binding protein
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Table 1.2 – Continued.
Year

Target(s)a and
agr (+/-)b

2011

Strategy

Model

Major in vivo Positive Results

Author

Hlb+, CAMP

Active Hlb, Passive
CAMP

Ms SSSI

↓Dermonecrosis

(116)

2010

Hla+

Active, passive Rb

Ms SSSI

↓Abscess, dermonecrosis

(117)

2010

Spa

-

Active, passive Rb

Ms bacteremia

↓Abscesses and CFU

(111)

2007

AIP4+

Passive Ms

Ms SSSI, bacteremia

↓Abscess, dermonecrosis; ↑Survival

(103)

2006

IsdA+, IsdB+, SdrD+, SdrE+

Active

Ms bacteremia

↑Survival

(118)

Active

Ms bacteremia, Rh titers

↑Survival; ↑Titer, long lasting

(106)

2006

a

IsdB

+

Hyphenation of target antigens indicates conjugation, while commas indicate combined antigens. bSuperscript +/- denotes positive or negative agr regulation, respectively.

Abbreviations: AIP4 - autoinducing peptide 4; CAMP - Christie-Atkins-Munch-Peterson factor; CFU - colony forming unit; Hla, Hlb - alpha-, beta-hemolysin; IsdA, B - iron-regulated surface
determinant A, B; Ms - mouse; Rb - rabbit; Rh - rhesus; SdrD, E - serine-aspartate repeat D, E; SpA - Staphylococcal protein A; SSSI- skin and skin structure infection
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The strategy of inhibiting virulence via vaccination against a quorum sensing
target is astute because antibody blocking QS could downregulate many virulence
factors. This is especially significant when considering that many of the human clinical
trial antigens are agr-regulated and protection has been shown in animal models for
single or multiple antigens regulated by agr (Table 1.1 and Table 1.2). Although AgrB
and AgrC are extracellular, and thus accessible to antibodies, they are difficult targets as
AgrB and AgrC are membrane-bound and targeted vaccination may not generate
functional antibodies that block AIP secretion or binding, respectively. Similarly, the
secreted AIP macrocycle ranges from seven to nine amino acids and is labile in vivo due
to the five-membered thiolactone ring. The small size and lability of the active (cyclic)
molecule, prevents the direct use of AIP as a vaccine antigen. However, in 2007, Park et
al. pioneered QS vaccination by haptenizing a lactone AIP4-mimic to a protein carrier to
generate monoclonal antibody (mAb) AP4-24H11 (103). Passive transfer of the mAb
AP4-24H11 down-regulated agr-dependent virulence, protecting mice from SSSI and
bacteremia (103). Herein, Chapter 2 describes an active vaccination approach that builds
upon the protective anti-AIP mAb developed by Park et al. (112).

Small molecule inhibitors of quorum sensing
In addition to vaccine approaches to interfere with S. aureus QS, small molecule
inhibitors of QS are being actively investigated (reviewed in (37, 119)). In contrast to
active vaccine approaches, small molecules and antibodies can both be administered
therapeutically. However, small molecules have several beneficial attributes not found in
therapeutic antibodies. Monoclonal antibodies are expensive to manufacture and,
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although they are not rapidly cleared, large doses are required for efficacy (120).
Antibodies require secreted or extracellular targets because of membrane exclusion,
whereas small molecules can target both extracellular and intracellular targets due to their
size and, often, membrane permeability (121). Finally, chemical optimization following
lead compound identification has been highly successful, especially if the binding site has
been identified (122). These benefits suggest that small molecule inhibitors of QS would
also be useful in the fight against S. aureus.
Natural products, compounds produced by any organism, are a wellspring of
bioactive small molecules as evidenced by their substantial contributions to anti-cancer
and anti-infective therapeutics (123). Impressively, 77% of antibacterial therapeutics in
the past 30 years are natural products or derived from natural product pharmacophores
(123). Encouragingly, natural products have several beneficial attributes not found in
chemical libraries or combinatorial chemistry approaches. Natural products are a
massively diverse and vast set of structures unmatched by combinatorial and synthetic
chemistry libraries (124, 125). Additionally, natural products often successfully break
Lipinski’s rules for ‘drug-like’ molecules (126) and often contain many chemical
moieties avoided by medicinal chemists (e.g. -quinones, polyhydroxyls) (127, 128). This
is likely due to the co-evolution of structures with biological targets, a sort of “biological
validation,” to quote Lahlou (129, 130). Finally, multiple bioactive natural products may
synergize naturally, and their utility as multi-component drugs is beginning to be
recognized (122, 129, 130). In light of these benefits, it is not surprising that most of the
QS inhibitors identified to date are natural products.
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The first studied natural product small molecule inhibitors of QS were the cross
interfering AIPs, which are competitive inhibitors of AgrC (40–43). Further work in the
field identified truncations of AIPs, mutated AIPs and peptides from other microbes
(solonamide A and B) that are known to inhibit QS (37, 119). However, the lability of the
thiolactone and amino acid side chains (57), the relatively short half-life (131), the
hypermutability of AgrC (132), and the requirement of a specific inhibitor per agr type
severely limit their utility clinically. In a similar matter, the peptide inhibitors of SpsB,
which is involved in AIP processing, are not as labile as the thiolactone AIPs but
presumably suffer from the same short half-life due to their peptidic nature (133). Even
more importantly, the most potent SpsB inhibitory peptide is also antibacterial and carries
the threat of resistance development, which is contrary to the goals of QS inhibition
(133). As described above, the RIP peptide, which is part of the RAP system, will not be
described due to continuing debate about its relevance (91, 92).
Interestingly another bacterial QS signal, the Gram negative P. aeruginosa
homoserine lactone (HSL) inhibits S. aureus QS (134, 135) and its synthetic analogues
have shown efficacy in a mouse arthritis model. The HSLs are thought to act either via
inhibition of a membrane sensor (e.g. - sarA), allosteric inhibition of AgrC dimerization,
or inhibition of AgrC interaction with AgrA (134, 135). However, these molecules have
inherent antibacterial activity at concentrations above the putative agr inhibitory
concentrations, which makes separating QS effects due to direct agr versus growth
inhibition difficult (134, 135). Additionally, membrane binding and insertion of the HSL
is required for S. aureus QS-inhibitory activity (although a receptor may be involved),
and this potential rote membrane perturbation may contribute to the mechanism of action
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(134, 135). Similarly, a quinolone from P. aeruginosa can inhibit agr signaling, although
it drives formation of small-colony variants, enhances antibiotic resistance, and is
antibacterial (37, 132).
Other microbial products that inhibit S. aureus QS include the dipeptides of
Lactobacillus reuteri, proline-phenylalanine and proline-tyrosine, and these molecules
inhibit agr signaling potentially though competitive binding of AgrC (136). Ambuic acid,
isolated from an unidentified fungus, inhibited agr activation and hemolysin production,
and may act by inhibition of AIP production (137). High-throughput screening of
actinomycete cultures has also identified potential agr inhibitors (138). Additionally,
indole and derivatives, produced by enteric bacteria, have been shown to inhibit
staphyloxanthin and Hla production, reduced agr-regulated transcription, and protected
against S. aureus in a Caenorhabditis elegans virulence model (139). Furthermore,
polyhydroxyanthraquinones isolated from Penicillium restrictum isolated from a milk
thistle (Silybum marianum), demonstrated potent inhibition of agr-I QS as measured by
luminescent agr reporter and reduction in δ-toxin production (140). Herein, Chapter 3
characterizes the most potent of the polyhydroxyanthraquinones, ω-hydroxyemodin,
which is efficacious in a mouse model of SSSI and functions by binding to AgrA
inhibiting activation of cognate promoters (141).
Many plant derived natural products have also been identified that inhibit agr
promoter activity and/or agr-regulated transcripts or toxins, but their mechanisms of
action have not been identified. These include: (a) licochalcone A and E from licorice
root (Glycyrrhiza inflata) (142, 143); (b) thymol from thyme (Thymus vulgaris) (144); (c)
luteolin derived from many plants (145); (c) α-cyperone isolated from a Chinese herb
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(Cyperus rotundus)(146); (d) ethanolic extracts of Italian plants (Ballota nigra, Castanea
sativa, and Sambucus ebulus) (147); (e) extracts of the goldenseal (Hydeastis canadensis)
(148); (f) salicylic acid, the active metabolite of aspirin from willow bark (Salix alba)
(149); and (g) puerarin, found in many plants (150). It should be noted that compounds ac have antibacterial effects at high concentrations, but agr inhibition is evidenced at subinhibitory concentrations. There are additional reports of plant-derived structures, but
their antibacterial activities make determination of true agr-dependent effects difficult
(151, 152).
Although natural products have several beneficial attributes, chemical libraries
have also proven effective at identifying bioactive molecules (123). In this regard, several
traditional chemical library screens have resulted in compounds active against S. aureus
QS. The National Cancer Institute’s small molecule library was virtually screened against
the AgrA phosphorylation site and identified multiple aryl compounds, including
diflunisal, which inhibited Hla production, AgrA DNA-binding activity, and transcription
of agr-regulated genes (153). Virtual screening of the lead optimized Maybridge Ro3
fragment library for AgrA binding compounds identified three aryl compounds that dose
dependently inhibited AgrA DNA-binding activity (154). Furthermore, a screen of the
NIH Molecular Libraries Small Molecule Repository identified several compounds that
inhibited agr activation (155) and ultimately led to the identification of savirin (55).
Savirin was shown to be largely specific to agr inhibition, showed efficacy in a mouse
model of SSSI and did not induce resistance in vivo (55). Additionally, surface plasmon
resonance was recently used to demonstrate direct binding of savirin to AgrA, providing
a mechanism of action for agr inhibition (Pamela Hall, unpublished data).
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Concluding remarks and hypotheses
The prevalence and range of diseases caused by S. aureus, together with the crisis
of antibiotic resistance, suggest that a multi-pronged strategy, including both prophylactic
(vaccine) and therapeutic approaches, will be required to limit human disease.
Encompassing both approaches, we hypothesized that bacterial disarmament through the
inhibition of agr quorum sensing will both complement immune function and mitigate
the severity of S. aureus infection. As outlined below and in Figure 1.2, the studies
presented in Chapter 2 and Chapter 3 test this hypothesis using both an active vaccine
and a natural product approach to QS inhibition.
In Chapter 2, we utilize a previously described mAb, AP4-24H11, which binds
and neutralizes AIP4 (103), to develop an active S. aureus vaccine. Specifically, we
hypothesized that (a) AP4-24H11 could be used to identify a mimotope of AIP4 from a
random library of phage displayed peptides, and (b) that this mimotope could in turn be
used in a virus-like particle (VLP) based vaccine to generate protection against
subsequent infection by an S. aureus agr-IV isolate.
In Chapter 3, we seek to validate ω-hydroxyemodin, the most potent of several
natural product polyhydroxyanthraquinones identified by Figueroa et al. (140), as a
universal S. aureus agr inhibitor. We hypothesized that ω-hydroxyemodin would inhibit
QS in all four agr types, and would reduce disease severity in an agr-dependent model of
S. aureus SSSI by inhibiting production of agr-regulated virulence factors while
concomitantly bolstering the immune system. In addition, since the power of
combinatorial chemistry is greatly enhanced by target and, ultimately, binding site
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identification (122), we sought to determine the mechanism of action by which ωhydroxyemodin inhibits S. aureus agr.
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Figure 1.2 – Model for inhibition of the S. aureus accessory gene regulator via
vaccination or small molecule inhibition. The agr operon is depicted with antibodies
(A) or small molecules (B) inhibiting the function of the operon. (A) Antibody binding of
the secreted AIP molecule sequesters the signal from reaching the AgrC receptor (solid
line), thus preventing agr activation. (B) ω-Hydroxyemodin is depicted with potential
sites for agr inhibition (dashed lines). Inhibition of AgrB processing of AIP prevents
mature AIP from being secreted, halting agr signaling. Inhibition of AgrC by AIP
competition, preventing dimerization, or preventing interaction with AgrA ceases agr
signaling. Finally, inhibition of AgrA binding to target promoter DNA prevents
transcription of the regulatory RNAIII, stopping signaling.
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Abstract
A major hurdle in vaccine development is the difficulty in identifying relevant target
epitopes and then presenting them to the immune system in a context that mimics their
native conformation. We have engineered novel virus-like-particle (VLP) technology that
is able to display complex libraries of random peptide sequences on a surface-exposed
loop in the coat protein without disruption of protein folding or VLP assembly. This
technology allows us to use the same VLP particle for both affinity selection and
immunization, integrating the power of epitope discovery and epitope mimicry of
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traditional phage display with the high immunogenicity of VLPs. Previously, we showed
that using affinity selection with our VLP platform identifies linear epitopes of
monoclonal antibodies and subsequent immunization generates the proper antibody
response. To test if our technology could identify immunologic mimotopes, we used
affinity selection on a monoclonal antibody (AP4-24H11) that recognizes the
Staphylococcus aureus autoinducing peptide 4 (AIP4). AIP4 is a secreted eight amino
acid, cyclized peptide produced from the S. aureus accessory gene regulator (agrIV)
quorum-sensing operon. The agr system coordinates density dependent changes in gene
expression, leading to the upregulation of a host of virulence factors, and passive transfer
of AP4-24H11 protects against S. aureus agrIV-dependent pathogenicity. In this report,
we identified a set of peptides displayed on VLPs that bound with high specificity to
AP4-24H11. Importantly, similar to passive transfer with AP4-24H11, immunization
with a subset of these VLPs protected against pathogenicity in a mouse model of S.
aureus dermonecrosis. These data are proof of principle that by performing affinity
selection on neutralizing antibodies, our VLP technology can identify peptide mimics of
non-linear epitopes and that these mimotope based VLP vaccines provide protection
against pathogens in relevant animal models.

Introduction
The small particulate nature and multivalent structure of virus-like particles cause them to
provoke strong immune responses and make them effective scaffolds for displaying
heterologous antigens in a highly immunogenic format. Peptide-based vaccines are
typically poorly immunogenic, however, peptides displayed on the surface of VLPs elicit
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high-titer and long-lasting antibody responses (156–160). Although VLPs can be utilized
to increase the immunogenicity of peptides, identifying relevant target epitopes and then
presenting them to the immune system in a highly immunogenic context that mimics their
native conformation, has largely been an unpredictable process of trial-and-error. The
most widely used method for epitope identification is through affinity selection using
peptide libraries displayed on a filamentous phage. This technology has identified the
epitopes of many monoclonal antibodies (mAbs), and is a powerful technique for
mapping linear epitopes and discovering peptide mimics of conformational and nonpeptide epitopes. Nevertheless, peptides displayed on a filamentous phage are typically
poorly immunogenic due to the low valency display of peptides on the phage surface.
Thus, epitopes identified by phage display must be produced synthetically, linked to a
carrier, and displayed in a structural context unrelated to the selected phage. Often, in this
new conformation the peptides have vastly decreased affinity for the selecting molecule
and frequently lose the ability to induce antibodies that mimic the selecting antibody.
VLP technology has not previously been adapted for use in epitope identification
because recombinant VLPs are not well-suited for the construction of diverse peptide
libraries. Insertion of heterologous peptides into viral structural proteins often result in
protein folding and VLP assembly defects (161–163). To overcome these limitations, we
engineered a version of the bacteriophage MS2 coat protein whose folding and assembly
is highly tolerant of short peptide insertions (162). This system has allowed us to generate
large, complex libraries of VLPs displaying random peptide sequences. Because VLPs
encapsidate the mRNA that encodes coat protein and its peptide (162, 164), VLPs with
specific binding characteristics can be affinity selected and then the nucleic acid encoding
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the selected peptide can be recovered by RT-PCR. Most importantly, the same VLP can
be used for both affinity selection and immunization. Thus, this system integrates the
power of epitope/mimotope discovery of traditional phage display with the high
immunogenicity of VLPs. We recently showed the utility of this VLP technology to
identify linear epitopes and to elicit the proper antibody response by performing affinity
selection using a set of well-characterized mAbs (165).
In this study we used this VLP vaccine discovery platform to identify
immunogenic mimics of a quorum-sensing peptide from the Gram positive pathogen
Staphylococcus aureus. S. aureus is the leading cause of skin and soft tissue infections
(SSSI) presenting to emergency departments in the United States (13). The S. aureus
accessory gene regulator (agr) quorum-sensing system coordinates a density dependent
switch in gene expression that includes upregulation of virulence factors critical for
invasive SSSI (56, 103, 131, 166). The agr system signals through the use of a secreted
thiolactone-cyclized autoinducing peptide (AIP) which, upon binding to its cognate
surface receptor AgrC, initiates a regulatory cascade leading to changes in transcription
of more than 200 genes (44, 167). Among the upregulated genes are those encoding
secreted virulence factors essential for invasive skin infection, including upregulation of
the pore-forming toxin alpha-hemolysin (Hla). Infection with agr or hla deletion mutants,
loss of the Hla receptor ADAM10, or neutralization of Hla significantly attenuates
virulence in mouse models of SSSI (44, 56, 117, 168–170). Furthermore, we and others
have shown that host innate effectors which disrupt agr-signaling also provide defense
against S. aureus infection (57–60, 171). These results suggest that a VLP-based epitope
identification approach to vaccine development targeted towards disruption of agr
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signaling would be efficacious against S. aureus SSSI.
Among S. aureus strains there are four agr alleles (agrI to agrIV) and strains
from a given allele secrete a unique thiolactone cyclized AIP (AIPI to AIPIV) ranging
from seven to nine amino acids in length. Due to their size, these peptides are inherently
non-immunogenic. To overcome this, Park et al. described the production of a
monoclonal antibody (AP4-24H11) against a synthetic AIP4 hapten that binds with nM
affinity to AIP4 and that largely did not bind to other AIP family members, including
AIP1 (µM affinity), which differs by a single amino acid (103, 172). The crystal structure
of AP4-24H11 bound to AIP4 reveals that the antibody recognizes the characteristic AIP
thiolactone ring conformation, but does not interact with the N-terminal, linear region
(173). Importantly, passive transfer of AP4-24H11 protected against S. aureus
pathogenicity in a mouse model of dermonecrosis and against a lethal intraperitoneal S.
aureus challenge. The protection afforded by AP4-24H11 administration occurred
without affecting normal bacterial growth, confirming that the AP4-24H11 mechanism of
action was specific to inhibiting S. aureus virulence. Therefore, this work provided proof
of principle that antibodies targeting AIP could be efficacious against S. aureus SSSIs
(103).
We aimed to develop an active vaccine to provide protection against S. aureus
agr-mediated pathogenesis. Traditionally, subunit vaccines utilize whole proteins,
domains or epitopes conjugated to a carrier. We initially produced Qß VLPs with many
copies of chemically conjugated AIP1 peptide, but they failed to elicit a protective
response in the dermonecrosis mouse model (unpublished data). This failure may have
resulted from potential instability of the native AIP molecule (103). For example, the
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conformational restraint imposed by the AIP thiolactone bond is necessary for binding
AgrC and induction of agr-signaling, as linearization of the AIPs results in loss of
function. Furthermore, oxidation of the C-terminal methionine of AIP1 or AIP4 by hostgenerated reactive oxygen species is sufficient to inactivate the peptides. Thus, if the
VLP-linked AIPs became linearized or oxidized during the conjugation or vaccination
process, they would no longer be presented to the immune system as an authentic
antigenic target. Therefore, we pursued the novel approach reported here using our
affinity selection technology and the previously reported AP4-24H11 mAb targeting S.
aureus AIP4.
Our approach was to identify peptides that immunologically mimic AIP4. Starting
with random sequence peptide libraries on MS2 VLPs, we conducted biopanning on the
AP4-24H11 mAb and identified 8 different VLPs displaying peptides that specifically
bound the antibody. Vaccination with two of these VLPs elicited an immune response
that protected in a S. aureus mouse model of dermonecrosis. These data demonstrate the
feasibility of our VLP technology to identify immunologic peptide mimics of
conformational epitopes and the potential to develop efficacious vaccines against
otherwise non-immunogenic, conformationally constrained peptides such as those
regulating S. aureus agr-dependent virulence. To our knowledge, this is the first report of
an efficacious active vaccine targeting the secreted autoinducing peptides of the S. aureus
agr quorum-sensing system.

Materials and Methods
Plasmid construction and random peptide libraries
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The plasmids pDSP62 and pDSP62(am) were previously described (165). Briefly,
pDSP62 expresses the single chain dimer of the MS2 coat protein under the control of the
inducible T7 promoter. VLPs produced using pDSP62 contain 90 copies of the displayed
peptide per VLP. pDSP62(am) is the same construct except it contains an amber stop
codon at the junction of the two coat protein monomers in the single chain dimer. The
pDSP62(am) vector produces VLPs that display peptides at low valency (~3 copies of the
peptide per VLP) when expressed in a E. coli strain containing pNMsupA a plasmid that
expresses an alanine-inserting, amber suppressing tRNA under the control of the lac
promoter. The suppressor mediates occasional read through of the stop codon, so that
pDSP62(am) produces a mixture of wild-type coat protein and the peptide-displaying
single-chain dimer, which then coassemble into a mosaic VLP.
We have previously constructed random peptide plasmid libraries for use in our
VLP affinity selection protocol that display peptides in the downstream AB loop of the
MS2 single chain dimer coat protein (165). Briefly, oligonucleotides were synthesized
with 6, 7, 8 or 10 NNS codons, where N represents an equimolar mixture of all four
nucleotides and S is an equal mixture of C and G. NNS codons encode all 20 amino acids
and only a single stop codon. Using the Kunkel method, we produced plasmid libraries of
at least 1010 individual transformants for each peptide library. All plasmids in this study
were isolated using Qiagen Qiafilter or minipreps kits (Qiagen, Valencia CA).

VLP production and purification
Plasmid libraries from affinity selection or single plasmids containing defined sequences
that bound to AP4-24H11 were electroporated into the E. coli, T7 expression strain

36

C41(DE3) (Lucigen, Middleton WI) and grown to mid-log phase. Coat protein
expression was induced by the addition of IPTG (1 mM, Sigma-Aldrich, St. Louis MO)
for three hours and bacteria were collected by centrifugation and the pellet was stored at
–20°C overnight. Bacteria were lysed in SCB buffer (50 mM Tris, pH 7.5, 100 mM
NaCl) by addition of 10 µg/ml of lysozyme, sonicated and purified from bacterial debris
by centrifugation. The supernatant was treated with 10 units/mL of DNaseI (SigmaAldrich, St. Louis MO) and the VLPs were purified away from contaminating bacterial
proteins by size exclusion chromatography using sepharose CL-4B resin (Sigma-Aldrich,
St. Louis MO). Fractions that contained VLPs were combined and precipitated by the
addition of ammonium sulfate at 50% saturation. Precipitated VLPs were collected by
centrifugation, solubilized in SCB buffer and dialyzed in SCB overnight (Slide-a-lyzer
cassettes 20,000 MWCO, Millipore, Billerica MA). Purified VLPs were quantitated by
Bradford assay (Biorad, Hercules CA) and analyzed by agarose gel electrophoresis and
by SDS gel electrophoresis.

Affinity selections
VLP affinity selection was performed on the neutralizing AIP4 monoclonal antibody
AP4-24H11 (a generous gift from Gunnar Kaufmann and Kim Janda, Scripps Research
Institute). VLP affinity selections were performed as previously described (165). Briefly,
for the initial round of selection, we coated Nunc MaxiSorp ELISA plates (eBiosciences,
San Diego, CA) with 250 ng of AP4-24H11 in PBS overnight at 4°C. After washing,
wells were blocked with 0.5% nonfat dry milk in PBS and the four VLP-peptide libraries
(2.5 µg each of VLPs displaying 6, 7, 8 and 10 mers) were applied to the blocked wells
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for 2 hours (10 µg total VLP/well). After extensive washing (PBS), bound VLPs were
eluted with 0.1 M glycine, pH 2.7 and immediately neutralized by the addition of 1/10
volume of 1 M Tris, pH 9. To make enriched VLP libraries for subsequent rounds of
affinity selection, RNA from the eluted VLP were reverse transcribed and the RT
products (containing the downstream coat protein and AB loop peptide) were amplified
by PCR, digested with Bam HI and Sal I, and ligated into the pDSP62(am) vector.
Ligation products were electroporated into the E. coli 10 G bacterial strain (Lucigen,
Middleton WI), with a one-hour outgrowth and then immediately placed into 100 mL of
LB media containing 60 µg/mL of kanamycin. After overnight growth, plasmids were
isolated (Qiafilter Midi kit, Valencia CA) and used for VLP production for the next round
of affinity selection. All plasmid libraries constructed after affinity selection contained at
least 106 individual transformants. Two additional rounds of affinity selection were
performed with low valency peptide display (~3 peptides/VLP); one using 250 ng of
mAb per well and the final round used 50 ng of mAb per well.

Identification and characterization of VLPs
After the final round of affinity selection, plasmid libraries enriched for VLPs displaying
peptides that bound to the AIP4 mAb were isolated as described above. 1 pg of each
library was electroporated into the C41(DE3) E. coli strain to ensure single transformants
and bacteria were plated on agar plates containing kanamycin. The next day, single
colonies were grown in 1 mL LB to an A600 of 0.6 and induced for VLP production with
the addition of IPTG for 3 hours. Before induction, a 100 µL aliquot was removed for
subsequent plasmid isolation. VLPs were isolated by sonication in SCB buffer and
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genomic DNA digested by incubation with 10 units of DNaseI. Crude VLP preps were
assayed for binding to AP4-24H11 or an unconjugated control mouse IgG (Jackson
ImmunoResearch Laboratories, West Grove PA) by ELISA. VLPs that bound to AP424H11 at least 5-fold higher then IgG control were further analyzed.
Plasmids were isolated from bacteria that produced VLPs that specifically bound
to AP4-24H11, but not control antibody. Nucleotide sequences encoding the various
peptides were determined (Eurofins Genomics, Huntsville AL) and plasmids encoding
unique peptide sequences were electroporated into C41(DE3) for large scale VLP
isolation as described above.
SDS PAGE and agarose gel electrophoresis was used to assess the purity and
characterize the isolated VLPs. We ran 2 µg of total protein on a 10% NuPAGE SDS gel
(Life Technologies, Grand Island NY) and stained the gel for total protein using
Coomassie Blue (BioRad, Hercules CA). Since VLPs encapsulate their RNA we could
also characterize VLP selectant particles by electrophoresis on an agarose gel. 10 µg of
VLPs were run on a 1% TBE agarose gel containing ethidium bromide.

ELISA
ELISA was used to assess relative binding of VLP selectants to AP4-24H11. Briefly,
wells were coated with 250 ng of purified VLPs in PBS and incubated overnight at 4°C.
Wells were washed 3 times with PBS and blocked for 1 hour using 3% BSA. Different
concentrations of AP4-24H11 in 3% BSA were applied to each well, and incubated at
room temperature for 1 hour. Unbound antibody was removed by washing with PBS.
Goat anti-Mouse IgG HRP conjugated antibody (Jackson ImmunoResearch Laboratories,
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West Grove PA) was diluted 1:5000 in 3% BSA and incubated for 1 hour at room
temperature. ABTS solution (EMD Millipore, Billerica MA) was used to detect bound
HRP antibody and color change was measured by absorbance at 405 nm (Opsys Plate
Reader, Thermo Scientific, Waltham MA).
For competition ELISAs, plates were prepared as above. AP4-24H11 (100
ng/well) was mixed with different concentration of the cyclical, bioactive AIP4 peptide
(10 µM–0.1 µM) for 10 minutes prior to incubation with VLPs. Secondary antibody and
detection was the same as above. As control peptides, we used a linear form of AIP4 or a
cyclical peptide from the L2 protein of human papillomavirus 16.

Immunization and skin infection model
Animal studies were carried out in accordance with the recommendation in the Guide for
the Care and Use of Laboratory Animals, the Animal Welfare Act, and U.S. federal law.
The protocol was approved by the Institutional Animal Care and Use Committee
(IACUC) of the University of New Mexico Health Sciences Center. Four to six week old
female Balb/c mice (Harlan Laboratories, South Easton MA) were immunized with 10 µg
of VLPs in PBS (50 µL total) without the addition of adjuvant by intramuscular injection
into the caudal thigh muscle. The initial immunization was followed with 2 boosts each 2
weeks apart. The initial experiment used 3 mice for each VLP and subsequent
experiments used 5 mice per vaccine candidate. As negative controls, 2 groups of mice
were immunized with either PBS alone or a control VLP (displays no peptide).
The dermonecrosis model of mouse skin infection was previously described and
performed with minor modifications (174). Briefly, one week after the final vaccine
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boost, mice were anesthetized with isoflurane and inoculated subcutaneously with 1×108
CFU of early-exponential phase S. aureus agrIV (AH1872–MN TG; generously provided
by Dr. Alex Horswill, University of Iowa (175)). Animals were monitored for weight loss
and lesion formation for three days post-infection. Lesion formation was assessed by
measuring the maximal width and length of the abscess and necrotic ulcer with calipers.
Area of the abscess was determined using the equation A = (π/2)×L×W, while the
necrotic ulcer area was determined using the equation A = L×W (117). On day three
post-infection animals were euthanized by CO2 asphyxiation and abscesses (2.25 cm2
area) were collected. The tissue was homogenized and serially diluted for CFU
enumeration.

Cytokine analysis of abscess tissues
Abscess homogenates were stored at –80°C until cytokine analysis. Homogenates were
rapidly defrosted at 37°C and clarified by centrifugation at 12,500×g for 10 minutes.
Cytokine concentrations in clarified supernatants were determined using a custom
designed multiplex assay performed as per manufacturer’s recommendations (EMD
Millipore, Billerica, MA). The assay was read on a Bio-Plex 200 instrument and data
analyzed using the Bio-Plex Manager Software (Bio-Rad, Hercules, CA).

Alpha-hemolysin Western blot
Frozen homogenates were thawed and clarified as described above. Briefly, clarified
tissue homogenate was separated by SDS-PAGE on a 16% Tris-glycine gel (Life
Technologies, Grand Island, NY) before transfer to a polyvinylidene fluoride membrane.
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After blocking using TBST (20 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween 20) with
5% non-fat dry milk, immunodetection was performed using an anti-Staphylococcus
alpha hemolysin antibody (Abcam, Cambridge, MA). Immunoreactive band intensity was
determined using a FluorChem R System and AlphaView software (ProteinSimple, Santa
Clara, CA). Relative intensity is the ratio of measured intensity divided by the total
protein concentration based on absorbance at 280 nm.

Statistical analysis
Statistical significance was determined using GraphPad Prism v.5.04. The two-tailed
Student’s t-test was used for analysis of in vitro data, and in vivo data were analyzed by
the Mann-Whitney U test for non-parametrics. Results were considered significantly
different at p<0.05.

Results
In order to identify mimotopes of the AIP4 mAb AP4-24H11 epitope, we performed
affinity selection on AP4-24H11 using our random sequence peptide libraries displayed
on MS2 VLPs. The basic methodology is found in (Figure 2.). We used a mixture of four
libraries, each displaying 6-, 7-, 8- or 10-amino acid inserts, with each library containing
more than 1010 transformants (162, 165). We find that many antibodies have strong
preferences for peptide sequences of specific lengths, and using a mixture increases the
probability of finding optimal binding peptides. Three iterative rounds of affinity
selection were performed, each at increasing stringency; in round 2 we increased the
stringency by reducing the display valency from 90 to about 3 peptides per particle. In
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round 3 stringency was further increased by reducing the amount of antibody 5-fold to 50
ng. Reaction of the selectant population with AP4-24H11 was monitored by ELISA after
each round. By the end of round 3 binding was elevated more than 200-fold (data not
shown).
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Figure 2.1 - VLP affinity selection to identify mimotopes of mAb AP4-24H11. Wells
of an ELISA plate were coated with the mAb AP4-24H11 and were incubated with VLP
libraries displaying random peptides. RNA sequences from bound VLPs were recovered
by RT-PCR and re-cloned into VLP expression constructs and VLP libraries enriched for
peptides binding to AP4-24H11 were produced. Three rounds of biopanning were used
and clones of the resulting VLPs were sequence for peptide identification and subsequent
functional analysis.
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Ten cloned, round 3 selectants were subjected to sequence analysis, which
identified 8 different peptide sequences (Figure 2.B). The peptide sequence SGIMPH
was found in 3/10 selectants, while the other seven clones had unique sequences. When
performing affinity selections on antibodies with linear epitopes, families of related
sequences are often encountered. However, there was little primary sequence homology
amongst the different peptides, with the exception of peptide 2 and peptide 3. Furthermore,
none showed sequence identity to AIP4 (Figure 2.A) suggesting that these peptides

somehow structurally mimic AIP4, or that they bind an antibody paratope distinct from
that occupied by AIP4.
The AP4-24H11 selectant VLPs were expressed in E. coli and purified by
procedures we have described elsewhere (162). Their elution behavior from the gel
filtration matrix Sepharose CL-4B shows that each assembles into a particle the size
expected of the VLP (not shown). Figure 2.C shows the electrophoretic behavior of each
VLP in agarose. Since only intact particles contain RNA, their staining with ethidium
bromide verifies their intactness. Differences in electromobility are due mostly to charge
differences imparted by the presence of the peptides on the VLP surface. To assess the
purity of the VLP preparation prior to binding assays and immunizations, we analyzed
protein content by SDS-PAGE followed by Coommassie blue staining. VLPs (single
chain dimer ~28 kD) were effectively purified away from contaminating bacterial protein
(Figure 2.D).
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Figure 2.2 - Identification and purification of affinity selected VLP displayed
peptides. (A) The sequence and structure of the AIP4 peptide. (B) 10 VLP clones were
sequenced after three rounds of VLP affinity selection. Peptide inserts are shown and
demonstrate little primary sequence homology to the native AIP4 peptide. (C) Agarose
gel analysis of purified VLPs. RNA staining is indicative of intact VLPs (which
encapsulate their RNAs) and differences in VLP mobility are mostly due to differences in
the charges of the peptides displayed on the VLP surface. (D) SDS-PAGE. Two µg of
purified VLP protein were run of a 10% SDS gel and protein was detected by staining the
gel using Coommassie Blue.
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A direct ELISA was used to confirm that the affinity selected VLPs bound
specifically to AP4-24H11. VLPs were used as the coating antigen (250 ng/well) and
various amounts (0.1 to 500 ng) of AP4-24H11 were added to each well. AP4-24H11
bound to all of the VLPs displaying the selected peptides, whereas little to no binding of
AP4-24H11 was observed with a control VLP (Figure 2.A). The selected VLPs
demonstrated a range of binding to AP4-24H11 with a ~3.5-fold difference between the
strongest binder (VLP displaying peptide 5) and the lowest (VLP displaying peptide 8).
As an additional control, VLP coated wells were incubated with a mouse IgG control
antibody using the same dilutions as used with the AIP4 mAb. Little or no binding was
detected with the control antibody for any VLP samples (data not shown).
To ensure that selecting VLPs are binding to the antigen-binding site of AP424H11 rather than the Fc region, we investigated the ability of bioactive AIP4 peptide to
compete with VLPs for antibody binding. VLPs were the coating antigen, and prior to the
addition of AP4-24H11 (100 ng/well) various amounts of bioactive AIP4 peptide (10
µM–0.1 µM) were incubated with the mAb. The peptide/antibody mixture was added to
the VLP coated wells and incubated for 1 hour. Similar to the results shown in Figure
2.A, there was a range of peptide concentrations required to inhibit antibody binding
(Figure 2.B). Importantly, all VLPs were competed off the antibody by bioactive AIP4,
suggesting that the selected VLPs are interacting with the antigen binding site of AP424H11.These data demonstrate that affinity selection can identify a population of VLPs
displaying peptides that bind specifically to the mAb AP4-24H11.
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Figure 2.3 - Affinity selected VLPs bind to and occupy the antigen binding site of
mAb AP4-24H11. (A) ELISA was used to assess specific binding of VLP selectants to
AP4-24H11. Wells were coated with the indicted VLPs and different concentrations of
AP4-24H11 were applied. Error bars represent standard error of the mean. (B) For
competition ELISAs, wells were coated with the indicated VLPs and AP4-24H11 was
mixed with different concentration of the cyclical, bioactive AIP4 peptide prior to
incubation with VLPs. Secondary antibody and detection was the same as above. As a
control peptide, we used a linear form of AIP4. Results are representative of an
experiment performed twice.
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Next, we tested whether any of the selected VLPs could serve as an immunologic
mimic of AIP4. Secreted virulence factors regulated by agr, such as Hla, mediate
dermonecrosis, suggesting that vaccination with VLPs presenting immunologic mimics
of the AP4-24H11 epitope would elicit protection against agrIV-mediated dermonecrosis.
To test this, we vaccinated groups of 3 mice with VLPs presenting AP4-24H11-selected
peptides or a VLP control, and challenged the mice by subcutaneous injection with S.
aureus agrIV isolate AH1872 (58) (Figure 2.A). We observed the mice for three days
post-infection as we typically see maximum ulcer development by this time point
followed by resolution over approximately the next seven days (55, 176). Compared to
VLP control vaccinated mice, mice vaccinated with peptide 4 VLPs showed significantly
reduced abscess area on days 1 and 3 post-infection (Figure 2.B). In addition, mice
vaccinated with either peptide 2 or peptide 4 VLPs showed a trend toward reduced
dermonecrosis (ulcer area) on days 2 and 3 post-infection, although this did not reach
statistical significance (Figure 2.C). Vaccination with VLPs displaying peptide 3 and
peptides 5–10 were included in pilot testing but no protection was observed, therefore
these VLPs were not included in further studies (data not shown).
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Figure 2.4 - Vaccination with VLP mimotopes of AIP4 is efficacious in a mouse
model of S. aureus SSSI. (A) Mice were vaccinated three times at two week intervals
with 10 µg of VLP. One week after the final vaccination mice were inoculated
subcutaneously with 1×108 CFU of S. aureus agr-IV isolate AH1872, and abscess (B)
and ulcer (C) areas were measured over the course of 72 hours. Data are shown as the
mean ± SEM of at least two independent experiments totaling 8–10 mice per group.
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Based on the reduced ulcer area in mice vaccinated with peptide 2 or 4 VLPs, we
asked whether vaccination with a combination of peptide 2 and peptide 4 VLPs (peptide
2/4-VLPs) would result in a significant reduction in dermonecrosis following S. aureus
challenge. To address this, mice were vaccinated with a mixture (1:1) of VLPs displaying
peptide 2 and 4, control VLPs or PBS alone, and then challenged by subcutaneous
injection with S. aureus AH1872. Whereas reductions in ulcer area in mice immunized
with either peptide 2- or peptide 4-VLPs alone failed to reach statistical significance,
mice immunized with combined peptide 2/4-VLPs had significantly reduced
dermonecrosis compared to control vaccinated mice on day three post-infection (Figure
2.A). Decreased ulcer area in peptide 2/4-VLP vaccinated mice was not due to a
reduction in bacterial burden at the site of infection (Figure 2.B) suggesting the
decreased dermonecrosis resulted from inhibition of agr signaling. In support of this
view, decreased dermonecrosis in the peptide 2/4-VLP vaccinated mice was associated
with a significant decrease in local IL-1β levels, but not decreases in IL-6 or
keratinocyte-derived chemokine (KC), compared to control vaccinated mice (Figure
2.C). Such a decrease in local IL-1β levels is consistent with reduced agr-mediated
expression of Hla, which causes pore-formation in host cells leading to NLRP3
inflammasome activation and IL-1β production (46, 177–182). To demonstrate that
reduced IL-1β at the site of infection in peptide 2/4-VLP vaccinated mice was associated
with decreased agr-mediated virulence factor expression, we measured Hla in tissue
homogenate by Western blot analysis. As expected, peptide 2/4-VLP vaccinated mice
had significantly less Hla at the site of infection compared to controls (Figure 2.D).
Together, these data suggest that peptides 2 and 4 identified by VLP affinity selection can
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serve as immunologic mimics of the S. aureus AIP4 mAb AP4-24H11 epitope and
provide protection against agr-mediated dermonecrosis.
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Figure 2.5 - A combination vaccine of two VLP mimotopes limits pathogenesis in a
mouse model of S. aureus dermonecrosis. Mice were vaccinated with 10 µg of a 1:1
suspension of peptide 2 and peptide 4 and inoculated with 1×108 CFU of AH1872 as
described previously. At the apex of infection (day 3) (A) abscess and ulcer area were
measured and (B) bacterial burden at the site of infection was determined, and (C) local
cytokine and chemokine levels were determined. (D) Western blot showing relative HLA
levels in tissue homogenate of vaccinated and challenged mice. Quantification based on
Western blot band intensity relative to total protein concentration. Data are shown as the
mean ± SEM of 6–10 mice per group. ns, not significant; *, p<0.05; **, p<0.01.
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Discussion
Recent technological advances have resulted in the isolation and characterization of a
host of broadly neutralizing monoclonal antibodies having prophylactic and therapeutic
effects against a variety of pathogens. We have developed a novel vaccine technology
that takes advantage of these newly identified antibodies that allows for epitope discovery
and mimicry on a highly immunogenic platform. We recently reported the use of this
VLP selection platform to identify epitopes for several previously characterized mAbs
that recognize linear epitopes (165). In this paper, we extend these observations by
identifying peptide mimics of the conformational epitope from the S. aureus AIP4 mAb
AP4-24H11. Of critical importance is that compared to controls, co-immunization with
two of the selected VLP candidates limited agr-signaling and pathogenesis during S.
aureus SSSI as indicated by (1) decreased expression of the agr-regulated virulence factor
Hla, (2) reduced local levels of the inflammatory cytokine IL-1β and (3) reduced
dermonecrosis. Furthermore, although immunization did not impact bacterial burden at
the time point evaluated, we and others have shown that, along with preventing or
limiting dermonecrosis, disruption of agr-signaling or neutralization of Hla leads to
increased bacterial clearance during resolution of infection (55, 168, 183). This suggests
the potential for vaccination with VLP-based AIP mimotopes to not only limit agrdependent pathogenesis, but also to eventually contribute to host-mediated bacterial
clearance. Importantly, these data provide proof-of-principle that our VLP technology
provides a background upon which to develop efficacious vaccines against otherwise
non-immunogenic, conformationally constrained epitopes. Antibodies are by nature
polyspecific. In the universe of all possible short peptide sequences, an antibody may be
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capable of binding a number of them. Therefore, it is possible that only some affinityselected peptides will bind the antigen-combining site through interactions mimicking
those of the authentic antigen. It is well known, for example, that M13 phage display
frequently finds so-called functional mimics, peptides that bind the antibody at paratopes
distinct from the antigen itself. When utilized as immunogens, functional mimics fail to
elicit antibodies with the desired specificity against the original antigen. We suspect
functional mimics are especially readily encountered with antibodies like AP4-24H11
whose binding sites have not been optimized for binding to a simple linear peptide
epitope. Immunogenic mimics, on the other hand, form molecular contacts with the
selecting antibody similar to those that engage the antigen itself, and are therefore more
likely to provoke antibodies that bind the antigen. Even in these cases, without detailed
structural analysis it may be impossible to discern any obvious structural similarity
between the original epitope and its affinity-selected immunogenic mimic. Of the 10
peptides we characterized here, 8 are apparently in the functional mimic category; they
bind the antibody but fail to elicit antibodies with specificity for AIP4. However, two
peptides elicited antibodies that served as immunogenic mimics as determined by their
ability to provoke an immune response that protected against S. aureus-mediated
dermonecrosis.
To date, no anti-Staphylococcus aureus vaccine has succeeded in Phase III
clinical trials (78). Such vaccines have primarily relied on immunization with S. aureus
surface protein antigens, suggesting that strategies aimed at inducing opsonophagocytic
antibodies are not sufficient to prevent disease by this pathogen. We are not alone in
recognizing the possible utility of vaccines that target secreted virulence factors (108,
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184). For example, neutralization of the secreted virulence factor Hla using active
vaccination or passive transfer of neutralizing antibodies has proven efficacious in
several S. aureus infection models (96, 117, 170, 181, 182, 185, 186) and a vaccine
targeting recombinant Hla was part of a recent clinical trial (NCT01011335). The
previous example is one of several strategies based on inhibition of a single secreted
virulence factor; however, immune-based approaches to inhibit S. aureus virulence factor
expression on a global level have been limited (reviewed in (184)).
Park et al. recently demonstrated in vivo protection via passive administration of a
mAb, directed against a synthetic AIP4 hapten, which prevents global virulence factor
expression by inhibiting agr quorum sensing (103). However, the availability of both
prophylactic vaccines and therapeutic mAbs targeting S. aureus agr-regulated virulence
would significantly increase the translational spectrum of this anti-staphylococcal
virulence approach. Herein, we expanded on the work of Park et al. using MS2 VLP
libraries and affinity selection to develop a vaccine strategy for agr-inhibition. Using this
technique against the mAb AP4-24H11, we identified candidate vaccines with in vivo
efficacy in a mouse model of S. aureus SSSI.
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Abstract
Antibiotic-resistant pathogens are a global health threat. Small molecules that inhibit
bacterial virulence have been suggested as alternatives or adjuncts to conventional
antibiotics, as they may limit pathogenesis and increase bacterial susceptibility to host
killing. Staphylococcus aureus is a major cause of invasive skin and soft tissue infections
(SSSIs) in both the hospital and community settings, and it is also becoming increasingly
antibiotic resistant. Quorum sensing (QS) mediated by the accessory gene regulator (agr)
controls virulence factor production essential for causing SSSIs. We recently identified
ω-hydroxyemodin (OHM), a polyhydroxyanthraquinone isolated from solid-phase
cultures of Penicillium restrictum, as a suppressor of QS and a compound sought for the
further characterization of the mechanism of action. At concentrations that are nontoxic
to eukaryotic cells and subinhibitory to bacterial growth, OHM prevented agr signaling
by all four S. aureus agr alleles. OHM inhibited QS by direct binding to AgrA, the
response regulator encoded by the agr operon, preventing the interaction of AgrA with
the agr P2 promoter. Importantly, OHM was efficacious in a mouse model of S. aureus
SSSI. Decreased dermonecrosis with OHM treatment was associated with enhanced
bacterial clearance and reductions in inflammatory cytokine transcription and expression
at the site of infection. Furthermore, OHM treatment enhanced the immune cell killing of
S. aureus in vitro in an agr-dependent manner. These data suggest that bacterial
disarmament through the suppression of S. aureus QS may bolster the host innate
immune response and limit inflammation.
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Introduction
Due to the widespread and seemingly inevitable development of bacterial resistance to
antibiotics shortly after their introduction, there is a great need for alternatives or adjuncts
to classical antimicrobials (8, 187, 188). Along with ongoing efforts to identify novel
antibacterial targets, interventions that are not directly bactericidal may prove efficacious.
These include approaches aimed at modifying or augmenting the host response, as well as
approaches that inhibit bacterial virulence mechanisms and thus limit pathogenesis (8,
187, 188). Many pathogenic bacteria coordinate the expression of virulence factors
important for invasive infection and pathogenesis through a density-dependent
communication system called quorum sensing (QS) (36, 52). Therefore, approaches
aimed at disrupting QS hold promise to limit pathogenesis in the host and/or serve as
adjuncts to extend the utility of existing antibiotics (36, 53, 54, 189–191).
Skin and soft tissue infections (SSSIs) represent the majority of infections caused
by Staphylococcus aureus (3, 12, 13), and many of the virulence factors contributing to
SSSIs are globally regulated by the accessory gene regulator (agr) (Figure 1.A) (38, 44,
167). The agr system utilizes a small secreted autoinducing peptide (AIP) to activate a
receptor histidine kinase, AgrC, in the bacterial cell membrane. AgrC phosphorylates the
transcription factor AgrA, which in turn activates transcription at the P2 and P3
promoters of the operon. P3 activation drives the production of the effector of the operon,
RNAIII, which regulates the expression of >200 virulence genes that contribute to
invasive infection (44). S. aureus isolates have one of four agr alleles (agr-I to agr-IV),
each encoding factors that secrete a unique AIP (AIP1 to AIP4, respectively; Figure 1.B)
that is detected by a cognate AgrC histidine kinase; isolates from each allele can cause
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human disease (192, 193). Importantly, we and others have shown that the disruption of
agr signaling by mutagenesis, monoclonal antibodies, or host factors limits S. aureus
infection and reduces pathogenesis (44, 56–58, 60, 103, 194), demonstrating that agr QS
is a robust target for combating invasive S. aureus infection.
Recently, we reported on a synthetic small molecule inhibitor of S. aureus QS
called savirin, providing proof of principle that small molecule-mediated inhibition of QS
can be efficacious against S. aureus in vivo (55). Natural products also represent a wealth
of bioactive compounds, as approximately 65% of the antibacterials introduced in the last
30 years are natural products or compounds designed based on a lead natural-product
pharmacophore (123). Therefore, we extended our search for inhibitors of QS to natural
products and in doing so identified a series of polyhydroxyanthraquinones isolated from
cultures of the fungus Penicillium restrictum that inhibited S. aureus QS (140). Among
these, ω-hydroxyemodin (OHM) (Figure 3.) demonstrated the most potent activity for
inhibiting agr-I signaling. Therefore, we sought to characterize OHM as an inhibitor of
agr signaling and to evaluate its efficacy in vivo.
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Figure 3.1 - Structure of ω-hydroxyemodin (OHM).
Molecular mass, 286.24 Da.
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Approaches aimed at augmenting the host response and those aimed at inhibiting
bacterial virulence mechanisms provide alternatives to conventional antibiotic therapy.
However, these two approaches are not mutually exclusive, and because many S. aureus
virulence factors antagonize the host innate immune response, we proposed that
inhibiting bacterial virulence would itself augment host defense. Specifically, we
postulated that small molecule-mediated disruption of S. aureus QS-dependent virulence
would not only limit pathogenesis but would also reduce inflammation and result in
enhanced bacterial clearance. Here, we report that OHM inhibits S. aureus QS by isolates
from all four agr alleles at concentrations that are noncytotoxic to S. aureus or eukaryotic
cells. Mechanistically, OHM inhibits agr activation by binding directly to AgrA and
blocking binding to agr promoter DNA. Importantly, as predicted, OHM limits tissue
damage and inflammation and promotes bacterial clearance in a mouse model of S.
aureus SSSI. In addition, OHM promotes the killing of agr+, but not agr-negative, S.
aureus by both mouse macrophages and human polymorphonuclear leukocytes (PMNs),
and it limits neutrophil lysis caused by agr-regulated S. aureus-secreted virulence factors.
This is the first report of a polyhydroxyanthraquinone with in vivo efficacy against S.
aureus QS-dependent virulence. In addition, these data demonstrate that antivirulence
approaches can limit disease by disarming the bacteria while concurrently bolstering host
innate defense.

Materials and Methods
Ethics statements

62

The animal work in this study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals (195), the
Animal Welfare Act, and U.S. federal law. The protocol was approved by the
Institutional Animal Care and Use Committee of the University of New Mexico Health
Sciences Center. The polymorphonuclear cells were isolated from whole blood samples
from consenting healthy human volunteers, according to the protocol (no. 11-005)
approved by the Human Research Protections Office of the University of New Mexico
institutional review board.

Bacterial strains and growth conditions
Methicillin-resistant S. aureus (MRSA) strain USA300 LAC (agr-I) was provided as a
generous gift from Frank DeLeo (Rocky Mountain National Laboratories, National
Institutes of Health, Hamilton, MT). S. aureus strains AH1677 (agr-I), AH430 (agr-II),
AH1747 (agr-III), and AH1872 (agr-IV) expressing yellow fluorescent protein (YFP)
under the control of the agr::P3 promoter were previously described (175).
Staphylococcus epidermidis strain AH3408 (agr-I) expressing superfolder green
fluorescent protein (sGFP) under the control of the agr::P3 promoter was also previously
described (41). S. aureus strains AH3469 (AgrC wild type [WT]) and AH3470 (AgrC
R238H) are described below. Unless otherwise noted, the bacteria were cultured at 37°C
and 220 rpm, with at least a 5:1 air-to-culture ratio in trypticase soy broth (TSB) (Becton,
Dickinson and Company, Sparks, MD). Early exponential-phase bacteria were prepared
as described previously (196). The frozen stocks were maintained at −80°C in TSB
supplemented with 10% glycerol. The bacteria were enumerated by serial dilution and
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plating onto trypticase soy agar containing 5% sheep blood (Becton, Dickinson and
Company), followed by overnight incubation at 37°C. The limit of detection was 2-log10
CFU.

agr::P3 promoter activation assays
Overnight cultures of S. aureus agr::P3 reporter strains were grown in TSB supplemented
with 10 μg/mL chloramphenicol (Cam). The cultures were diluted 1:250 into fresh TSB
with Cam, and 100-μl aliquots were transferred to 96-well microtiter plates (Costar 3603;
Corning, Tewksbury, MA) prefilled with 100 μL of medium and a 2-fold serial dilution
series (200 to 0.1 μM) of OHM. OHM was purified from solid-phase cultures of P.
restrictum, as described previously (140), and was >95% pure, as measured by ultrahighperformance liquid chromatography (UPLC) (Figure 3.).
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Figure 3.2 - The purity of OHM was evaluated via a Waters Acquity UPLC system
(Waters Corp., Milford, MA, USA). UPLC utilized a Waters BEH C18 column (1.7
μm; 2.1×50 mm) and a CH3CN-H2O gradient that increased linearly from 20 to 100%
CH3CN over 4.5 min. The chromatogram was monitored at 254 nm.

65

After mixing in the microtiter plate, the effective dilution was 1:500, and the final
OHM concentration ranged from 100 to 0.05 μM, with a final dimethyl sulfoxide
(DMSO) concentration of 0.1% (vol/vol) in all wells. Four dilution series were prepared
for each reporter; in addition, 4 mock DMSO dilution series were included for each
reporter strain. The microtiter plates were incubated at 37°C with shaking (1,000 rpm) in
a Stuart SI505 incubator (Bibby Scientific, Burlington, NJ) with a humidified chamber.
Fluorescence (top reading of 493 nm excitation, 535 nm emission, and gain of 60) and
optical density at 600 nm (OD600) readings were recorded at 30-min increments using a
Tecan Systems (San Jose, CA) Infinite M200 plate reader.
S. epidermidis AH3408 (agr-I::P3-sGFP) was cultured overnight in TSB
supplemented with 10 μg/mL erythromycin (Erm). To collect exogenous S. epidermidis
AIP1 peptide, the spent medium was centrifuged at 3,000×g, passed through a 0.2-μm
HT Tuffryn membrane (Pall, Port Washington, NY), and stored at −20°C until use. An
overnight culture of AH3408 was diluted 1:200 into 500 μL of TSB (broth) or TSB with
10% spent medium containing 5 μg/mL OHM or DMSO (vehicle). The cultures were
incubated for 24 h at 37°C, centrifuged, and resuspended in 10% formalin fixative for 1
min. The cultures were washed twice by centrifugation and resuspended in phosphatebuffered saline (PBS). The mean channel fluorescence (MCF) of sGFP was analyzed
using an Accuri C6 flow cytometry system (BD Biosciences, San Jose, CA). The data
were normalized to the broth cultures containing no exogenous AIP1.

Quantitative PCR
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For transcriptional quantification of mouse mRNA, 2.25-cm2 sections of skin including
and surrounding the abscess were excised, minced, and stored in RNAlater (Qiagen,
Valencia, CA) at −20°C until use. mRNA was purified using the RNeasy kits (Qiagen),
and cDNA was generated using a high-capacity RNA-to-cDNA kit (Applied Biosystems,
Foster City, CA). Quantitative PCR was performed using an ABI 7900HT real-time PCR
system with TaqMan Gene expression master mix, according to the manufacturer's
directions (Applied Biosystems). Predesigned primer and probe sets (Integrated DNA
Technologies, Coralville, IA) were used for the quantitation of mouse il-6, il-1β, tnfα,
nlrp3, and hprt. The data are represented as the fold increase relative to hprt compared to
that in uninfected tissue.
For the quantification of S. aureus gene transcription, 500-μL cultures at 2 × 107
CFU/mL of LAC and/or LACΔagr were grown in TSB at 37°C, with aeration, for the
indicated times with 50 nM exogenous AIP1 (Biopeptide Co., Inc., San Diego, CA) and
treatments (vehicle versus OHM), as indicated in the appropriate figure legends. The
bacteria were stored at −20°C in RNAprotect cell reagent, according to the
manufacturer's recommendations (Qiagen), until the RNA was purified as previously
described (55). cDNA generation and quantitative PCR (qPCR) were performed as
described above for eukaryotic qPCR. The primer and probe sets for the quantification of
the S. aureus genes are listed in Table 3..
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Table 3.1 – Oligonucleotides used for S. aureus qPCR.
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Rabbit red blood cell lysis assay
The assay was performed as previously described (197). Briefly, LAC was cultured in 5
mL of TSB for 8 h with the indicated treatments, centrifuged, and the supernatants were
filtered through a 0.2-μm HT Tuffryn membrane (Pall). Serial 2-fold dilutions of the
supernatant were incubated at 37°C for 1 h in a 4% solution of rabbit red blood cells
(rRBCs). Lysis was assessed spectrophotometrically at OD450. The data were analyzed by
nonlinear regression fit to a four-parameter logistic curve and represented as the HA50,
which equals 1/the dilution required for 50% complete lysis.

AgrC constitutive reporter assay
The agrBDCA operon was amplified from strain LAC using the primers AgrB+RBS 5′–
KpnI (GTTGGTACCCAGTGAGGAGAGTGGTGTAAAATTG) and AgrA 3′-SacI
(GTTGAGCTCCTTATTATATTTTTTTAACGTTTCTCACCGATG) and ligated into
pRMC2 (198). To make a variant with constitutive AgrC activity, we chose the AgrC
R238H mutation, which was previously shown to have similar activity in the presence
and absence of the AIP2 inhibitor and maximal activity in the absence of AIP1 (43). The
AgrC R238H variant was generated by the QuikChange (Agilent Technologies) sitedirected mutagenesis method, using the primers AgrC R238H fwd
(CAACGAAATGCGCAAGTTCCATCATGATTATGTCAATATC) and AgrC R238H
rev (GATATTGACATAATCATGATGGAACTTGCGCATTTCGTTG). To build a
destination strain for assessing alpha-hemolysin production, we selected an agrC
transposon mutant (NE873) from the Nebraska Transposon Mutant Library (199) and
integrated the pLL29 plasmid at the phage 11 attachment site to confer tetracycline
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resistance (200). The above-described pRMC2 constructs were transformed into this
strain to make reporters AH3469 (AgrC WT) and AH3470 (AgrC R238H). To test OHM,
AH3469 and AH3470 were grown overnight with 10 μg/mL Cam and were diluted 1:500
into 5 mL of fresh medium with 10 μg/mL Cam and 0.025 μg/mL anhydrotetracycline.
AIP2 control, OHM, or DMSO (vehicle) was added to each strain at the concentrations
indicated. The cultures were grown at 37°C and shaken at 220 rpm for 6.5 h. The bacteria
were pelleted by centrifugation, and the alpha-hemolysin-containing supernatants were
passed through a 0.2-μm HT Tuffryn membrane (Pall). Rabbit red blood cell lysis assays
were conducted as above but with an rRBC concentration of 1% and 25% supernatant
(vol/vol) to yield complete lysis. The values are presented as the mean relative lysis
compared to that with vehicle treatment.

Eukaryotic cytotoxicity
A549, HEK293, or HepG2 cells were seeded in a 96-well tissue culture plate at 2.5 × 104
cells per well and incubated at 37°C with 5% CO2. XTT [2,3-Bis(2-methoxy-4-nitro-5sulfophenyl)-2H-tetrazolium-5-carboxanilide] and phenazine methosulfate (PMS) were
purchased from Sigma-Aldrich (St. Louis, MO). The XTT assay was previously
described (201). After 24 h, the spent medium was removed, and fresh medium
containing the indicated drug concentrations or vehicle was added to the cells and
incubated for an additional 24 h. To avoid potential interference with the absorbance
readings due to the red color of OHM, drug-containing medium was replaced with 100
μL of 0.3 mg/mL XTT with 0.015 mg/mL PMS in Hanks' balanced salt solution (HBSS)
and incubated for 1 h. Cell viability was assessed by the metabolic reduction of
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tetrazolium measured at OD490. The data are presented as the percentage of viable cells
compared to that in the vehicle control.

EMSA and flow cytometry-based AgrAC promoter binding assays
Escherichia coli expressing the AgrA C-terminal DNA binding domain (AgrAC) along
with a 6-histidine tag was generously provided by Chuan He (University of Chicago,
Chicago, IL) and purified as previously described (202). Electrophoretic mobility shift
assays (EMSA) were performed as previously described (55), with purified AgrAC and
agr P2 promoter, and a 16-bp duplex DNA probe with a 3′ 6-fluorescein (P2-FAM)
(Integrated DNA Technologies, Coralville, IA). The duplex DNA contained the highaffinity LytTR binding site located in both agr P2 and P3 promoters (203). Briefly, 2 μM
AgrAC was incubated for 10 min at room temperature (RT) with vehicle or the indicated
concentrations of OHM in Tris-acetate-EDTA (TAE) buffer with 10 mM dithiothreitol
(DTT). Next, 20 ng of P2-FAM DNA probe was added and incubated for an additional
10 min. The reaction mixtures were loaded onto a 10% PAGE gel and run at 50 V in the
dark for 20 min. DNA migration was assessed by imaging on a FluorChem R system
(ProteinSimple, Santa Clara, CA).
For the flow-based AgrAC promoter binding assays, AgrAC was biotinylated
(AgrAC-BTN) using a Thermo Scientific EZ-Link sulfo-NHS-LC-biotin kit (Thermo
Scientific, Rockford, IL), according to the manufacturer's directions. AgrAC-BTN was
immobilized on 1-μm-diameter Dynabeads MyOne streptavidin T1 (Life Technologies,
Grand Island, NY) (AgrAC-SA), and the beads were suspended in PBS. DNA probe (P2FAM) was added at a final concentration of 1.6 μM, along with equimolar competing
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unlabeled P2, vehicle control, or OHM at the indicated concentrations. OHM-mediated
inhibition of AgrAC-SA binding to DNA probe was measured as decreased mean channel
fluorescence (MCF) compared to that of the vehicle control using an Accuri C6 flow
cytometry system (BD Biosciences).

In silico docking on AgrAC
In silico docking calculations were performed using the Macintosh binary executable of
AutoDock Vina (39). OHM was docked onto the B subunit of the AgrAC crystal structure
(RSCB Protein Data Bank [www.pdb.org], PDB ID 4G4K) (154, 204) stripped of
heteroatoms. The search box was restricted to the C-terminal region of AgrAC, as
described for 9H-xanthene-9-carboxylic acid (154). Based on initial observations
suggesting that OHM bound to the pocket between the side chains of His200, Arg218,
Tyr229, and Val232, additional calculations were run in which the size of search box was
varied and the side-chain torsion angles for different combinations of residues in the
region were allowed to be flexible. The reported docking solution was obtained by
allowing flexibility in the side chain torsion angles for His200, Arg218, Tyr229, and
Val232 and by using a search box that was large enough to include both the pocket
bounded by the side chains of His200, Arg218, Tyr229, and Val232 and the groove
between Val232 and Lys236. Molecular modeling images were prepared using PDB ID
3BS1 and PyMOL (PyMOL molecular graphics system, version 1.5.0.4; Schrodinger,
LLC).

Surface plasmon resonance analysis
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To overcome the potential interference for the oxidative inactivation of AgrAC during
surface plasmon resonance (SPR) analysis, the oxidation-resistant C199S mutation was
introduced into the AgrAC expression construct, as previously described (202), using the
QuikChange II XL kit (Agilent Technologies). His-tagged AgrAC-C199S was purified as
described previously (55) but without the addition of Tris(2-carboxyethyl)phosphine
(TCEP) or DTT during purification.
SPR binding and kinetics analyses were performed on a Biacore X100 instrument
(GE Healthcare, Pittsburgh, PA) and evaluated with Biacore X100 evaluation software
(version 1.0). His-tagged AgrAC-C199S was immobilized at 10 μg/mL in PBS on a
nitrilotriacetic acid (NTA) biosensor with the NTA reagent kit (GE Healthcare). For
binding studies, OHM (analyte) was dissolved in running buffer (PBS, 5% DMSO [pH
9]) and applied at a flow rate of 30 μL/min with a 180-s contact time and 300-s
dissociation time. The data were fit to a 1:1 binding model after the subtraction of blank
injections and the removal of injection spikes from the sensorgrams. NTA biosensor
chips were regenerated with the following sequence: two 60-s washes with 350 mM
EDTA, a 60-s wash with PBS, and a 60-s wash with 500 mM imidazole, followed by a
final 60-s wash with PBS. The analyses were performed at 25°C.

Mouse model of skin and soft tissue infection
The mouse model of skin and soft tissue infection was previously described and was
implemented with minor modifications (174). Early exponential-phase S. aureus strain
LAC was diluted into USP-grade saline (Braun, Irvine, CA) to deliver 5×107 to 7×107
CFU per mouse. Aliquots of OHM were diluted in 0.5% hydroxypropylmethylcellulose
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(HPMC) (pH 11) to deliver 0.2 mg/kg per mouse (∼5 μg). The mice were anesthetized
with 3% isoflurane at 3 liters/min. The bacteria and OHM were mixed 1:1 immediately
before subcutaneous injection into the right flank, at a total volume of 50 μL. The mice
were weighed prior to infection and every day post infection. Additionally, the injection
sites were photographed daily to determine the abscess and ulcer areas with ImageJ
analysis (205). On day three or day seven post infection, each mouse was euthanized by
CO2 asphyxiation, and a 2.25-cm2 section of skin surrounding the abscess was excised.
The tissue was mechanically homogenized and serially plated on sheep blood agar to
determine the bacterial burden. The tissue homogenates were stored at −80°C until they
were rapidly defrosted at 37°C for cytokine analysis. On day 3 post infection, the
homogenate was centrifuged at 12,500×g for 10 min and the clarified supernatant
analyzed with a custom-designed multiplex assay (Merck KGaA, Darmstadt, Germany)
using a BioPlex 200 with BioPlex Manager software (Bio-Rad, Hercules, CA). The
abscess tissues collected for hematoxylin and eosin (H&E) staining were fixed overnight
in 10% formalin and embedded in paraffin. Five-micrometer sections were then stained
with H&E and imaged using an Olympus IX70 microscope (Olympus, Center Valley,
PA).

Alpha-hemolysin quantification
For the detection of alpha-hemolysin (Hla) in abscess tissue homogenates by Western
blot assay, clarified homogenates were rapidly thawed and an aliquot electrophoresed on
a 16% Tris-glycine SDS-PAGE gel (Life Technologies, Grand Island, NY) before
transfer to a polyvinylidene fluoride membrane. The membranes were blocked for 1 h at

74

RT, using TBST (20 mM Tris [pH 7.5], 150 mM NaCl, 0.1% Tween 20) with 5% nonfat
dry milk. Hla was detected using anti-Hla antibody (ab15948; Abcam, Cambridge, MA)
at a 1:1,000 dilution and alkaline phosphatase-conjugated secondary antibody. The
immunoreactive bands were developed with nitroblue tetrazolium (NBT)/5-bromo-4chloro-3-indolyl-phosphate (BCIP) (Thermo Scientific) and intensity measured using a
FluorChem R system and the AlphaView software (ProteinSimple). Relative intensity
was calculated as the measured intensity divided by the total protein concentration based
on absorbance at 280 nm.

Mouse macrophage killing of S. aureus
Murine macrophage cells (RAW 264.7) were maintained at 37°C in 5% CO2 in highglucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 2 mM L-glutamine, 10 mM HEPES, with 100 U/mL penicillin and
100 μg/mL streptomycin. Twenty-four hours prior to the experiments, the RAW cells
were washed with PBS and the medium replaced with DMEM, as described above but
with 2% FBS without antibiotics. Early exponential-phase LAC or LACΔagr was
cultured in 3 mL of TSB at 2×107 CFU/mL at 37°C, with aeration for 5 h, with 50 nM
exogenous AIP1 (Biopeptide Co.) and 5 μg/mL OHM or DMSO (vehicle). The bacteria
were centrifuged, washed in PBS, sonicated, and suspended at 1×108 to 2×108 in DMEM
but with 1% FBS without antibiotics. The bacteria were opsonized overnight at 4°C with
rabbit anti-S. aureus IgG at 100 μg/mL (catalog no. YVS6881; Accurate Chemical &
Scientific Co., Westbury, NY). The RAW cells were washed with PBS and suspended at
2×107 cells/mL in DMEM with 1% FBS without antibiotics and combined with
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opsonized bacteria at a multiplicity of infection (MOI) of 1:1. The cells were centrifuged
at 500×g for 3 min to initiate contact and incubated at 37°C in 5% CO2 for 1 h to allow
phagocytosis. Lysostaphin (catalog no. L-0761; Sigma-Aldrich) was added at 2 μg/mL
for 15 min to kill extracellular bacteria and then removed by centrifugation and
replacement with fresh medium. Half of the samples were immediately processed for
CFU determination, and the other half were incubated for an additional 4 h before CFU
enumeration. Intracellular bacteria were enumerated by preliminary dilution into PBS–
0.1% Triton X-100, followed by sonication and plating onto blood agar.

Human PMN assays
PMNs were purified from normal healthy venous blood, as described by Nauseef (206).
The purified PMNs were suspended in HBSS without divalent cations at ≤3×107 cells/mL
and kept on ice until use.
PMN phagosomal killing of S. aureus was conducted as previously described,
with the following alterations (207). Prior to opsonization, early exponential-phase LAC
or LACΔagr was cultured in 3 mL of TSB at 2×107 CFU/mL at 37°C, with aeration for 5
h, with 50 nM exogenous AIP-I (Biopeptide Co.) and 5 μg/mL OHM or DMSO (vehicle).
The bacteria were centrifuged, washed in PBS, and opsonized at 5×106 CFU/mL in
HBSS, with divalent cations supplemented with 20 mM HEPES, 1% human serum
albumin (HSA), and 10% pooled human serum. Following a 20-min incubation with
tumbling at 37°C, the bacteria were pelleted, washed in PBS, and resuspended in HBSS
with divalent cations supplemented with 20 mM HEPES. The PMNs and opsonized
bacteria were combined at an MOI of 1:1 and incubated for 10 min at 37°C. The
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extracellular bacteria were removed by centrifugation at 500×g for 5 min, followed by the
resuspension of infected PMNs in HBSS with divalent cations supplemented with 20 mM
HEPES and 1% HSA. The infected PMNs were incubated at 37°C for 120 min, and the
aliquots were removed at 0, 30, 60, and 120 min. The aliquots were diluted into PBS–
0.1% Triton X-100 to lyse the cells and then serially diluted and plated on blood agar for
CFU enumeration.
The lysis of PMNs by the S. aureus supernatant was conducted as previously
described, with minor modifications (55). Briefly, LAC was cultured in 3 mL of TSB for
5 h with 5 μg/mL OHM or vehicle, centrifuged, and the supernatants were filtered
through a 0.2-μm HT Tuffryn membrane (Pall). The supernatants were stored at −80°C
and thawed on ice prior to use. The PMNs were washed with PBS and resuspended in
RPMI supplemented with 10 mM HEPES and 1% HSA. PMNs at a density of 3×106
cells/mL in 100 μL were added to 100 μL of RPMI, RPMI with 10% TSB (vol/vol), or
RPMI with 10% S. aureus supernatant prepared as described above. The PMNs were
incubated at 37°C and 5% CO2 for 2 h. Following incubation, the supernatants were
collected by centrifugation at 3,000×g for 5 min and assessed for lactate dehydrogenase
(LDH) release, according to the manufacturer's specifications (CytoTox 96
nonradioactive cytotoxicity assay; Promega Co., Madison, WI). Triton X-100 was added
at a final concentration of 0.1% (vol/vol) as a 100% lysis control, while cell-free RPMI
with 5% TSB served as a blank. The data are normalized to 100% lysis control.

Statistical analysis
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Statistical evaluations were performed using GraphPad Prism version 5.04. The in vitro
data were analyzed by the two-tailed Student's t-test, and the in vivo data were analyzed
by the Mann-Whitney U test for nonparametrics. The results were considered
significantly different at a P value of <0.05.

Results
ω-Hydroxyemodin is a universal inhibitor of S. aureus quorum sensing
Our original report focused on OHM inhibition of QS using an S. aureus strain derived
from the USA300 agr-I isolate LAC (140). However, isolates from all four agr alleles
contribute to disease in humans. Therefore, to be of maximum utility, a QS inhibitor must
antagonize QS by all four agr alleles. To address this, we assessed the ability of OHM to
inhibit quorum sensing by isolates of all four agr types using reporter strains expressing
yellow fluorescent protein (YFP) under the control of the agr::P3 promoter. OHM
inhibited QS by all four agr types at concentrations that do not impact bacterial growth
(Figure 3.A). Importantly, at concentrations required for agr inhibition, OHM was
nontoxic to human alveolar (A549), kidney (HEK293), and hepatocyte cell lines (Figure
3.B). Also as expected based on the inhibition of agr::P3 promoter activation, OHM
decreased the transcription of the agr effector RNAIII and agr-regulated virulence
factors, including phenol-soluble modulin alpha (psmα) and alpha-hemolysin (hla)
(Figure 3.A). OHM also inhibited the production of Hla, as demonstrated by the red
blood cell lysis assay (Figure 3.B). Therefore, these data demonstrate that at
concentrations that are noncytotoxic to eukaryotic cells, OHM is a universal inhibitor of
S. aureus QS.
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Figure 3.3 – ω-Hydroxyemodin inhibits S. aureus quorum sensing by all four agr
alleles. (A) Effect of OHM on agr::P3 promoter activation (open symbols) and cell
growth (closed symbols), measured by flow cytometry and OD600, respectively, for agr-I
(red circles), agr-II (blue squares), agr-III (green triangles), and agr-IV isolates (black
diamonds). (B) Percent cell viability of A549 (blue circles), HEK293 (red squares), and
HepG2 (green triangles) cells measured by XTT assay after 24 h of incubation with the
indicated concentrations of OHM. The dashed vertical lines indicate the concentration
used for the in vitro assays. Data are shown as means ± SEM. The experiments were
performed in triplicate or quadruplicate.

Figure 3.4 - OHM inhibits transcription and translation of agr-regulated genes. (A)
Quantification of RNAIII, psmα and hla by qRT-PCR relative to 16S following a 2 h
incubation of USA300 isolate LAC (2 x 107 CFU/mL) with 50 nM AIP1 and either 5
μg/mL OHM or vehicle control. Data are represented as the fold increase relative to 16S
as compared to inoculum bacteria, and normalized to broth with exogenous AIP. (B)
Effect of 5μg/mL OHM on expression of α-hemolysin (Hla) assessed via the rabbit red
blood cell lysis assay. HA50 is the bacterial supernatant dilution factor required for lysis
of 50% of the RBCs. Data are the mean ± SEM of triplicate samples. ns, not significant,
** p<0.01, ****p<0.0001, by Student’s t-est.
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ω-Hydroxyemodin antagonizes AgrA function
The ability of OHM to antagonize QS by all S. aureus agr alleles pointed to a target that
is well conserved in the system. Therefore, we first focused on AgrC, the receptor
histidine kinase activated by AIP binding. To determine whether OHM disrupted AgrC
activation, we tested OHM for the inhibition of agr-mediated Hla expression determined
by the lysis of rabbit RBCs, using an agr-I isolate expressing constitutively active AgrC
(R238H (43)). Whereas the addition of inhibitory AIP (AIP2) reduced Hla expression by
S. aureus expressing wild-type (WT) but not constitutively active AgrC, OHM inhibited
Hla expression by both isolates (Figure 3.A). These results support a mechanism of
action whereby OHM intracellularly inhibits agr signaling, downstream of AgrC
activation.
The response regulator AgrA functions downstream of AgrC, and we and others
have shown that small molecules that target AgrA disrupt QS (55, 154). Therefore, to
further address the mechanism of action of OHM, we evaluated potential OHM binding
sites on the crystal structure of the C-terminal AgrA DNA binding domain (AgrAC) (154,
208). The most favorable binding site for OHM was near the AgrAC-DNA interface
(Figure 3.B). Docking studies positioned OHM in a pocket between the side chains of
H200 and Y229, with Y229 recently identified as a major contributor to maximal AgrA
activity (209), and three residues, R218, S231, and V232, which make direct interactions
with bound DNA in the AgrA-DNA crystal structure (203). Given this, together with
observations that OHM is within hydrogen bonding distance of R218 and that naturally
occurring mutations at R218 result in agr-negative phenotypes (210), we predicted that
OHM would inhibit AgrA binding to promoter DNA.
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Figure 3.5 - ω-Hydroxyemodin inhibits AgrA binding to promoter DNA. (A) Effect
of OHM on agr::P3 promoter activation assessed by rabbit red blood cell lysis for AgrCWT isolate AH3469 and AgrC-R238H isolate AH3470. The data are the mean relative
lysis ± standard error of the mean (SEM) compared to the vehicle control. The
experiments were performed in triplicate. ns, not significant. (B) Space-fill model of
AgrAC showing potential binding site for OHM. Inset, ball-and-stick representation of
OHM binding site. (C) Flow cytometric bead-based assay to determine the effect of
OHM on the binding of P2-FAM to biotinylated AgrAC immobilized on streptavidin
beads (SA beads). Unlabeled P2 binding to immobilized AgrAC in competition with P2FAM was included as a specificity control. The data are the mean ± SEM (n = 3). (D)
Surface plasmon resonance analysis of OHM binding to 6-His-tagged AgrAC-C199S
immobilized on a nitrilotriacetic acid biosensor. The 50% inhibitory concentration (IC50)
was calculated as described in Materials and Methods. Kd, dissociation constant. *, P <
0.05; **, P < 0.01; ***, P < 0.001; ****, P ≤ 0.0001 by Student's t-test.
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To test this, we expressed AgrAC and measured binding to fluorescently labeled
duplex agr promoter DNA encompassing the high-affinity binding site located in the agr
P2 and P3 promoters (P2-FAM). As expected, OHM demonstrated a dose-dependent
inhibition of AgrAC binding to agr promoter DNA by an electrophoretic mobility shift
assay (EMSA) (Figure 3.A). In addition, we developed a bead-based assay to measure
transcription factor binding to target DNA using flow cytometry. Biotinylated AgrAC was
immobilized on streptavidin beads (SA beads), and the binding to promoter DNA was
measured by flow cytometry. As expected, OHM again demonstrated a dose-dependent
inhibition of AgrAC binding to agr promoter DNA (Figure 3.C). Furthermore, OHM
bound directly to immobilized AgrAC, as shown by surface plasmon resonance (SPR)
analysis (Figure 3.D). Finally, because the amino acid sequence in the predicted OHM
binding site of S. aureus AgrA is highly conserved with that of S. epidermidis AgrA, we
postulated that OHM would also inhibit agr signaling by S. epidermidis. As expected,
OHM significantly inhibited agr activation by agr-I S. epidermidis (Figure 3.B).
Together, these data strongly suggest that OHM inhibits agr signaling by binding to
AgrA and blocking AgrA function.
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Figure 3.6 – OHM inhibits the AgrA-DNA interaction and inhibits S. epidermidis
quorum sensing. (A) Effect of OHM on the electrophoretic mobility shift of the AgrA
DNA-binding domain (AgrAC) and P2-FAM complex (‘v’ indicates vehicle control). (B)
Effect of OHM on S. epidermidis agr::P3 promoter activation measured by flow
cytometry normalized to media control (Broth). Data are the mean ± SEM of experiments
performed in triplicate. ** p<0.01, by Student’s t-test.
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To begin to address the specificity of OHM for agr inhibition, we used qPCR to
evaluate the effects of OHM on transcription of a series of agr- and non-agr-regulated
genes involved in virulence, the stress response, metabolism, and drug efflux and
resistance (44, 55, 211, 212) (Table 3.). With respect to virulence genes, OHM treatment
resulted in a slight yet nonsignificant increase in the transcription of spa, which encodes
protein A and is negatively regulated by agr (44). In contrast, the expression of the
enterotoxin gene set7 decreased with OHM in LAC but not LACΔagr, and OHM had no
effect on the expression of the saeR component of the SaeRS virulence regulator.
Likewise, the transcription of genes involved in the stress response (asp23, crtM, and
clpB) was not altered by OHM, suggesting that OHM does not induce a general stress
response in LAC under the conditions tested (213–217). Among the metabolism genes
examined, OHM had no significant effect on the transcription of the genes involved in
electron transport (atpG and sdhA). However, OHM treatment significantly decreased the
transcription of murQ, an N-acetylmuramic acid 6-phosphate lyase, in both LAC and
LACΔagr. Although this protein, which is involved in cell wall recycling, is dispensable
for growth in E. coli (218–220), its contribution to the growth of Gram positive
pathogens is less clear. However, the absence of bactericidal or bacteriostatic effects with
OHM treatment suggests that MurQ is not required for growth under the conditions
tested. In addition, OHM treatment did not increase the transcription of genes examined
for their potential to contribute to drug efflux or resistance. Therefore, although there are
some non-agr effects, these results suggest that OHM is not a general inhibitor of
transcription or energetics, nor is it a general inducer of drug efflux.
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Table 3.2 – Transcriptional analysis of the agr specificity of OHM.
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Furthermore, together with the above demonstrations of (i) OHM-mediated agr
inhibition in a whole-cell assay, (ii) OHM-mediated inhibition of AgrAC binding to agr
promoter DNA by both EMSA and bead-based assay, and (iii) the direct binding of OHM
to AgrAC shown by SPR (Figure 3. and Figure 3.6), these results are consistent with a
mechanism whereby OHM predominantly functions as an inhibitor of agr activation.

ω-Hydroxyemodin attenuates S. aureus SSSI
Invasive S. aureus SSSIs require agr-regulated virulence factors (44, 56, 131, 166, 168).
Therefore, we assessed the efficacy of OHM in an established mouse model of S. aureus
SSSI (174). Over the course of a three-day infection with the USA300 isolate LAC, a
single 5-μg dose of OHM administered at the time of infection significantly inhibited
abscess (Figure 3.A, B) and ulcer (dermonecrosis) formation (Figure 3.A, C), as well as
morbidity at day one post infection (assessed by weight loss) compared to that of the
vehicle-treated controls (Figure 3.D). In contrast, no differences were observed between
the OHM and vehicle-treated mice infected with LACΔagr (Figure 3.A and data not
shown), demonstrating the specificity of OHM for disrupting agr signaling without
directly impacting the host. Importantly, the single OHM treatment reduced the day three
and day seven post infection bacterial burden at the site of infection in LAC-infected
(Figure 3.E) but not Δagr-infected mice (Figure 3.7F), suggesting that mice were better
able to combat the infection in the absence of agr signaling.
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Figure 3.7 - ω-Hydroxyemodin limits abscess formation and dermonecrosis and
promotes bacterial clearance in a mouse model of S. aureus SSSI. SKH1 mice were
subcutaneously injected with 5×107 to 7×107 CFU of LAC or Δagr along with OHM (0.2
mg/kg) or vehicle control. (A) Representative images of abscesses and ulcers on day
three post-infection (D3) (scale bar = 5 mm). Day 3 post-infection abscess (B), ulcer area
(C), and weight loss of LAC-infected mice. (E) Day 3 and day 7 post-infection bacterial
burden at the site of infection. The data shown are the mean ± SEM (LAC, day 3, n = 12
to 16 mice per group; day 7, n = 5 mice per group). (F) Δagr day 3 bacterial burden at the
site of infection. n = 6 mice per group. ns, not significant. *, P < 0.05; **, P < 0.01 by
Mann-Whitney U test.
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We predicted that if OHM treatment supported host-mediated clearance by
disrupting agr signaling, OHM-treated LAC, but not LACΔagr, would be more readily
killed by innate immune cells in vitro compared to in the vehicle-treated controls. As
predicted, OHM treatment of LAC, but not LACΔagr, resulted in significantly increased
intracellular killing by both mouse macrophages (Figure 3.A) and human PMNs (Figure
3.B) compared to that in the vehicle-treated controls. Furthermore, OHM treatment of
LAC but not LACΔagr protected human PMNs from killing by secreted agr-regulated
virulence factors. PMNs showed significantly increased survival in the presence of
supernatant from OHM- versus vehicle-treated LAC (Figure 3.C).The increased killing
was not a result of OHM-mediated effects on opsonophagocytosis, as the total number of
bacteria phagocytosed (Figure 3.D) and the percentage of bacteria phagocytosed relative
to the total inoculum (data not shown) were equivalent, regardless of whether the bacteria
were pretreated with vehicle or OHM. Together, these results demonstrate that OHM
supports the host-mediated clearance of S. aureus by inhibiting agr-mediated virulence.
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Figure 3.8 - ω-Hydroxyemodin supports immune cell killing of agr+ S. aureus. (A)
Mouse macrophage (RAW 264.7) intracellular killing of bacteria pretreated with OHM or
vehicle control. The data are shown as the mean ± SEM normalized to 100% after 1 h of
incubation at an MOI of 1:1. n = 6 from two independent experiments performed in
triplicate. (B) Human polymorphonuclear leukocyte (PMN) intracellular killing of
bacteria pretreated with OHM or vehicle control. The data are the mean ± SEM presented
as the percent survival (top) and log CFU reduction (bottom) compared to time zero. (C)
Supernatant lysis of human PMNs, assessed by LDH release, after 2 h of incubation with
sterile supernatant from overnight cultures grown in the presence of OHM or vehicle
control. The data are the mean ± SEM, presented as percent PMN viability compared to
100% lysis by Triton X-100. (B and C) (D) Effect of OHM pre-treatment of S. aureus on
the ability of PMN to opsonophagocytose bacteria. Data are the mean ± SEM, presented as
LogCFU of phagocytosed bacteria at time zero. Experiments were performed in triplicate
with PMNs from two separate donors. A representative donor experiment is shown. ns,
not significant. **, P < 0.01; ***, P < 0.001; ****, P ≤ 0.0001 by Student's t test.
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ω-Hydroxyemodin limits inflammation mediated by S. aureus QS
S. aureus uses a variety of virulence factors, many of which are regulated by the agr
system, to evade host clearance mechanisms. These virulence factors cause tissue damage
and inflammation and facilitate invasive infection (48, 83, 221–223). Therefore, we
postulated that the reduction in bacterial burden in the LAC-infected, OHM-treated mice
would be associated with reduced tissue damage and reduced local inflammatory
cytokine production compared to the vehicle-treated controls. Histological analysis of
day three post infection skin sections confirmed the overall reduction in abscess
formation and ulceration in OHM-treated mice (Figure 3.A). Additionally, skin sections
from the vehicle-treated mice displayed a disorganized architecture at both the
epithelium-to-necrosis transition (Figure 3.A, left inset) and the abscess periphery (right
inset) compared to sections from OHM-treated mice. Also as predicted, OHM treatment
resulted in a local cytokine profile matching that of LACΔagr-infected mice on day three
post infection (Figure 3.B), with significant reductions in interleukin-1β (IL-1β), tumor
necrosis factor alpha (TNF-α), and IL-6, but not the anti-inflammatory cytokine IL-10,
compared to the vehicle-treated controls. LAC-infected mice treated with OHM also
showed reduced transcription of il-1β, tnfα, and il-6 at 24 h post infection compared to
the levels in the vehicle-treated mice (Figure 3.C). Finally, the activation of the NLRP3
inflammasome and the subsequent release of IL-1β is induced by pore formation in the
host cell membranes by Hla (46, 177, 178), and the passive transfer of Hla-neutralizing
antibodies is sufficient to limit the secretion of IL-1β (181). Therefore, we predicted that
OHM treatment would be associated with reduced Hla expression and nlrp3 transcription
at the site of infection. As expected, the OHM-treated mice showed decreased local Hla
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expression and decreased transcription of nlrp3 compared to the vehicle-treated controls
(Figure 3.D, E). Together, these data demonstrate that OHM inhibition of agr signaling
limits host tissue damage and inflammation during S. aureus SSSI.
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Figure 3.9 - ω-Hydroxyemodin limits pathology and expression of inflammatory cytokines during S. aureus SSSI. (A) Top,
representative hematoxylin and eosin micrographs of 5-μm sagittal sections of day three post-LAC infection abscess tissue. The
abscess area is demarcated by a fine dashed line, while the ulcer surface length is marked by the thick dash line. Bottom,
magnification of the transition from normal epithelium to necrotic tissue (left) and organization of the abscess tissue (right). (B)
Multiplex analysis of cytokines present in the abscess tissue on day three post infection with LAC or Δagr. (C and E) Quantification
of il-1β, tnfα, il-6 (C), and nlrp3 (E) relative to hprt in abscess tissue at 24 h post-LAC infection. (D) Western blot analysis and
quantification of Hla at the site of infection (day 3) in OHM- versus vehicle-treated mice (n = 4 mice/group). The data are the mean ±
SEM from infection data, as described in the legend to Figure 3.. RQ, relative quantification; *, P < 0.05; **, P < 0.01; ***, P < 0.001
by Student's t test.
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Discussion
Recently, the National Institutes of Allergy and Infectious Diseases reported on the
current status and future directions for its antibacterial resistance program (9). Two of the
strategic approaches highlighted were (i) antivirulence strategies to disarm bacteria to
reduce pathogenesis and (ii) approaches to harness the host immune system to better
combat infections. Here, we report that OHM, a natural product isolated from the fungus
P. restrictum (140), addresses both goals by directly inhibiting S. aureus QS-dependent
virulence while indirectly bolstering the host immune response against S. aureus
infection. In a mouse model of S. aureus SSSI, OHM significantly decreases abscess and
ulcer formation and promotes bacterial clearance. Importantly, OHM treatment reduces
tissue damage and limits local proinflammatory cytokine production to levels seen in
mice infected with the agr deletion mutant. Furthermore, OHM treatment enhances
immune cell-mediated killing of S. aureus in an agr-dependent manner. Therefore, these
data demonstrate that antivirulence strategies can limit disease by disarming the bacteria
while concurrently reducing inflammation and promoting host innate defense. In
addition, this is the first polyhydroxyanthraquinone described with in vivo efficacy
against MRSA infection, adding to the expanse of natural products with the potential to
promote human health and advance antibiotic stewardship.
Numerous reviews have addressed the potential role of antivirulence strategies,
including the disruption of QS, in combating the antimicrobial resistance crisis (36, 53,
54, 184, 224, 225). We chose to focus on the disruption of agr QS as an antivirulence
approach to S. aureus SSSIs due to their predominance in S. aureus disease
manifestations, as well as the established contribution of agr in facilitating these
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infections (3, 12, 13, 44, 56). For example, agr deletion mutants (Δagr) are less
pathogenic and more readily cleared during SSSIs than are wild-type strains (44, 56), and
host innate effectors that disrupt agr signaling limit disease in skin infection models (57,
58, 194). Importantly, the sterile supernatant from agr+ but not from agr-null S. aureus
strains is sufficient to cause skin lesions similar to those in an active infection,
definitively demonstrating the role of agr-regulated secreted virulence factors in skin
pathogenesis (131). Here, we used OHM in a prophylactic administration model, similar
to that previously reported for the administration of competing AIP or the passive transfer
of monoclonal antibodies targeting AIP4 (103, 131), to demonstrate that small moleculemediated disruption of agr signaling in vivo results in an “agr-null-like” host
inflammatory profile.
The disruption of agr signaling during SSSIs results in reduced bacterial burden at
various time points post infection (55, 56, 131, 168), suggesting that host-mediated
bacterial clearance is more effective in the absence of QS. In support of this, we have
shown here and elsewhere (55) that agr inhibitors enhance some mechanisms of innate
immune bacterial clearance against agr+ S. aureus. The increased bacterial clearance
likely results from inhibiting the expression of the agr-regulated secretome, which
includes virulence factors that target host immune cells. Among these, the phenol-soluble
modulins (PSMs) and Hla, in particular, contribute to abscess formation, dermonecrosis,
and bacterial burden during SSSIs (117, 166, 168, 226). These toxins target a variety of
cell types to suppress both innate and adaptive immunity (227). For example, S. aureus
utilizes Hla to survive inside neutrophils and macrophages (207, 228–231) and to induce
programmed cell death in T cells, B cells, and monocytes (232). In addition, Hla activates
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the NLRP3 inflammasome in a variety of cells, resulting in the release of the
inflammatory cytokine IL-1β (177–179). Although neutrophils and IL-1β are needed for
the ultimate clearance of S. aureus SSSI (233, 234), limiting inflammation caused by
bacterial toxins clearly benefits the host.
Our molecular modeling studies positioned OHM near R218 of S. aureus AgrA.
This residue, which is strictly conserved across multiple staphylococcal species (209), is
required for agr function and contributes to AgrA binding to agr promoter DNA (203,
210). Although the potential exists for OHM to drive selection for an alternative amino
acid at residue 218, any such mutation would likely result in agr dysfunction. The
selection for QS-deficient isolates is unlikely to be of significant benefit to the pathogen,
as these isolates are severely attenuated, more readily cleared by host defenses, and less
effective at initiating infection (56, 168, 202). However, while the residues directly
involved in OHM binding have yet to be definitively demonstrated, the question of
whether OHM can select for mutation of other residues in the predicted binding site that
would prevent OHM function while retaining agr activity will require empirical
determination.
Along with inhibiting S. aureus agr activation, OHM likewise inhibits agr
signaling by S. epidermidis, an important member of the skin microbiome and also an
opportunistic pathogen (235). S. epidermidis agr regulation drives the mechanisms of
resistance to host innate defense (236), suggesting that OHM or related analogues might
prove efficacious against S. epidermidis infections. However, in its role as a commensal,
S. epidermidis appears to benefit the host by such means as competing with S. aureus for
colonization and contributing to overall skin immunity (237–239). Additionally, AIP1
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produced by S. epidermidis is cross-inhibitory to S. aureus agr types I to III in vitro (40,
42, 235). Therefore, it is unclear whether OHM-mediated perturbation of S. epidermidis
QS, during treatment for S. aureus SSSI, might result in unwarranted complications, such
as increased host-mediated clearance of S. epidermidis and/or the loss of potentially
beneficial cross-inhibitory AIP. To address these possibilities, it will be important to
experimentally determine the in vivo implications of disrupting QS in an S. epidermidiscolonized host on subsequent S. aureus skin infection.
As is the case with existing antimicrobials, QS inhibitors (QSIs) may not be a
one-size-fits-all solution. Although SSSIs comprise the vast majority of S. aureus
infections, this pathogen causes a variety of disease manifestations, including pneumonia,
osteomyelitis, endocarditis, and bloodstream infections (BSI). This raises the question of
whether the use of QSIs will be universally beneficial. The contribution of agr to S.
aureus pathogenesis has largely been demonstrated in models of SSSIs and pneumonia
(44, 56, 103, 131). In contrast, agr dysfunction has been associated with persistent
bacteremia in hospitalized patients (233, 234), suggesting that QSIs would be best
utilized to prevent S. aureus invasion prior to BSI. Likewise, the disruption of agr is
associated with biofilm formation in vitro (235), potentially limiting the utility of QSIs
for the treatment of infections involving implanted devices, as well as osteomyelitis and
endocarditis. Whether OHM and other QSIs would contribute to staphylococcal biofilm
formation in vivo will require investigation in appropriate animal models of infection.
Overall, however, QSIs might be a critical part of the developing arsenal for combating
antibiotic resistance either alone, as adjuncts to existing antibiotics, or along with
potential vaccines or other approaches to augment host defense.
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A substantial portion of the compounds used to fight infections have their origins
in natural products (123). Despite clearly representing a wealth of bioactive molecules,
natural products have received limited attention with respect to identifying specific
inhibitors of S. aureus QS that are not bactericidal. To date, other natural products
identified as agr inhibitors include (i) α-cyperone from the nut grass plant Cyperus
rotundus (146), (ii) the fungal metabolite ambuic acid (137), and extracts from (iii) the
goldenseal plant Hydrastis canadensis (148) and (iv) three Italian medicinal plants,
Ballota nigra, Castanea sativa, and Sambucus ebulus (147). Among these, OHM is the
first to demonstrate in vivo efficacy against S. aureus QS. Therefore, we predict that
targeted testing of structurally diverse natural products will continue to reveal a broad
range of antivirulence molecules with the potential to support innate host defense
mechanisms and to positively contribute to antibiotic stewardship.
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CHAPTER 4: Conclusions
Staphylococcus aureus is a global health threat causing significant morbidity and
mortality (14, 15). The exceptional capacity of this pathogen to acquire resistance and the
dearth of novel antibacterial therapies has led to the search for alternative treatment
strategies. Anti-virulence strategies focused on bacterial disarmament are one such
alternative strategy. S. aureus regulates over 200 virulence factors with the accessory
gene regulator operon that encodes a density-dependent quorum sensing system (44).
Many of the agr-regulated virulence factors are important for invasive infection, and this
is further evidenced by the significantly reduced pathogenesis of agr deletion mutants in
certain infection models (56, 240, 241). Therefore, targeting the agr operon represents an
attractive approach for prophylaxis or therapeutic intervention.
The work described herein, and summarized in Figure 4., significantly advances
the field of anti-virulence strategies to combat S. aureus as follows. First, in Chapter 2,
we report the development and demonstrate the efficacy of the first active vaccine
targeting a secreted AIP of the agr system. The small size and lability of the AIP
molecule has previously proven challenging for active vaccination. The use of stable
peptide mimotopes displayed with high valency on a virus-like particle overcomes the
AIP shortcomings and proved successful in limiting agr-dependent pathogenesis in vivo,
a significant advance in the field. Second, in Chapter 3, we demonstrate that a novel
natural product inhibitor of AgrA, ω-hydroxyemodin, leads to bacterial disarmament
which limits S. aureus pathogenesis and supports host innate defense resulting in
increased bacterial clearance. While several natural products agr quorum sensing
inhibitors have been described, specific mechanism of action studies have not been
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described and many of the inhibitors are innately antibacterial, muddling the
interpretation of agr inhibition. This work is significant for the field of natural products
because: (i) it identifies the agr target of ω-hydroxyemodin, the response regulator AgrA;
(ii) ω-hydroxyemodin has no antibacterial activity and is nontoxic to eukaryotic cells;
(iii) prophylaxis was proven efficacious in an animal model of SSSI; and (iv) inhibition
of agr resulted in a bolstering of the immune response to infection.
The discussion below will address criticisms of the approaches described,
experimental approaches to further the two intervention strategies, and finally a
discussion on potential clinical utility of quorum sensing inhibitors. Specifically, we will
address the suitability of targeting the agr operon in terms of resistance development,
biofilm enhancement, and the role of agr in S. aureus virulence regulation. Following
that will be a discussion on methodologies to enhance both the mimotope VLP vaccine
and the natural product ω-hydroxyemodin. The discussion will conclude with a
description of the clinical utility of quorum sensing inhibitors, including populations who
would benefit from treatment, potential for agr inhibitors in other S. aureus diseases, and
implications for quorum sensing inhibition for multiple pathogens.
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Figure 4.1 - Inhibition of the S. aureus accessory gene regulator quorum sensing via
vaccination or small molecule inhibition. The agr operon is depicted with the inhibitors
described in Chapters 2 and 3 and their protective effects in vivo. Mimotope generated
antibodies bind the AIP signal preventing activation of AgrC and subsequent agr
activation. ω-Hydroxyemodin binds the response regulator AgrA preventing interaction
and therefore transcription of agr promoters. Inhibition via either method results in
reduction of disease severity and inflammation in vivo. ω-Hydroxyemodin was also
specifically shown to enhance immune function in an agr-dependent manner.
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Suitability of targeting agr quorum sensing
Although the work reported here makes significant advances in addressing the feasibility
and efficacy of anti-virulence strategies, several questions remain unanswered. There are
three key questions regarding agr inhibition as a treatment modality: (i) will resistance to
agr inhibitors develop, (ii) will inhibition of agr, which prevents invasion, enhance
biofilm formation and (iii) what is the role of agr, as compared to other S. aureus
virulence regulators, in virulence regulation during different disease states?
One of the key hypotheses to inhibition of virulence is that because inhibition is
not directly antibacterial, resistance development should be minimal, if existent.
Resistance development is less likely for antibody approaches because the target, AIP
(AgrD), would have to mutate to prevent antibody sequestration. Mutation in AIP would
require concomitant changes in AgrB and AgrC, which makes resistance development
less likely. Resistance to ω-hydroxyemodin is more theoretically possible as it targets a
single protein, suggesting that mutations in AgrA that prevent ω-hydroxyemodin binding
could occur which do not affect the DNA-binding functionality of the protein. Recent
work in the Gram negative organism Pseudomonas aeruginosa suggests that QS
resistance may be possible (242–245), but whether these findings will apply to Gram
positive organisms remains to be determined. In contrast to the findings in P. aeruginosa,
the study reported by Sully et al. attempted to develop resistance in S. aureus to a small
molecule QS inhibitor by repeated in vivo passage of bacteria with the inhibitor (55). At
the conclusion of the experiment, bacteria passaged with the QS inhibitor were still
susceptible to QS inhibition, but bacteria passaged with an antibiotic control developed
resistance to the antibiotic over the same course of passage (55). In addition to mutations
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resulting in resistance to therapeutics, mutations resulting in agr inactivation would also
render antibodies and small molecules ineffective. Single inactivating mutations in AgrA
and AgrC exist in colonizing isolates and clinical isolates from bloodstream infections
(210, 246, 247). However, multiple mutations in agr are not found, suggesting
evolutionary selection for agr functionality exists and that these mutation are likely only
adaptive for survival in the current host (210). Additionally, transmission occurs only
infrequently between immunocompromised hosts, where agr may not be necessary, and
not stably into general circulation (210). Therefore it is unlikely that treatment induced
inactivation of agr will lead to dispersal of agr-negative strains.
One valid concern of agr inhibition is that while inhibition reduces virulence
factors resulting in invasive infection, it may favor the formation of biofilms due to the
upregulation of adhesive factor expression (38). This is a major concern where biofilm
formation is associated with disease, such as ventilator-associated pneumonia,
endocarditis, osteomyelitis and implanted medical devices. The role of agr in biofilm
formation, maturation and dispersal is multifactorial (38, 248, 249). The agr-regulated
phenol-soluble modulins and many proteases are involved in biofilm formation,
maturation, and most importantly dispersal (38, 248–250). Therefore, although agr
inhibition may in fact increase biofilm formation, the altered nature of the biofilm and the
prevention of dissemination may mitigate the concern (250, 251). However, many
questions about agr inhibition and the effect on biofilm formation have not been
addressed experimentally, especially in vivo. Until these questions are answered, agr
inhibitors would be clinically useful where biofilms are of less concern. For example,
prophylactically following surgery or trauma, or during an active skin infection,

102

enhancing adherence while preventing dissemination to the blood and subsequent
metastasis may be clinically acceptable. This is especially possible because incision and
debridement are current best practices and would help in biofilm clearance (16).
Additionally, because agr inhibition does not enhance MSSA biofilms (248), inhibition
of QS in MSSA strains, which cause almost half of the Staphylococcal SSSI presenting to
emergency departments (13), has significant clinical utility.
Another concern is that while inhibition of agr could have a significant clinical
impact, it is not the only regulatory pathway of importance in S. aureus. The twocomponent signaling saePQRS operon also has important roles in toxin and virulence
factor production (56, 252). Additionally, sarA regulates virulence via agr-dependent and
agr-independent mechanisms (253, 254). These additional systems possess DNA-binding
transcription factors (SaeR and SarA) which could be targeted via small molecule
inhibition in a similar manner to AgrA. A cocktail of inhibitors could be more efficacious
than a single inhibitor as evidenced by the further reduction of virulence in a double agr
and sarA or saeRS mutants (56, 255).

Future considerations for mimotope VLPs
One major limitation of mimotope selection, is that it requires an antibody for panning of
mimotopes. Therefore, this screening technique is limited to antigens for which
antibodies, particularly monoclonals, exist. Despite this requirement, VLPs possess many
intrinsic qualities that make them well suited for vaccine development (reviewed in
(156)). VLP-based vaccines are already FDA approved for the prevention of viral
infection. Due to the nature of the self-assembling repeating capsid, antigens are
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presented in a dense, repetitive array suitable for B-cell activation (156). Display of
antigens can be accomplished either through genetic insertion in surface exposed loops or
by chemical conjugation to exposed amino acids amenable to available chemistries (156).
The size of VLPs allow them to be efficiently phagocytosed by dendritic cells resulting in
presentation in both MHCI and MHCII contexts (156). VLPs are also relatively easy to
produce and are stable over a range of conditions (156). The excellent properties afforded
by VLP vaccination suggest that generation of mAb to novel antigens is a necessary,
although not convenient, first step for mimotope identification. This is especially true for
poorly immunogenic antigens, such as AIPs, that can generate highly-specific and
protective antibodies if additional steps are taken.
Another limitation is the agr type specificity of the vaccine. A prophylactic
vaccine would need to cover all four agr types to be of clinical utility. All of VLP-based
FDA approved human papillomavirus vaccines are multivalent, suggesting that if
mimotopes could be identified for all four AIPs they could be coadministered as a
vaccine. Additionally, the ability of VLPs to self-assemble presents an enticing
hypothesis for the formulation of an S. aureus vaccine. Another possible benefit of VLPs
could be whether the multivalent vaccines can be assembled with TH17/IL-17 adjuvants
or additional vaccine antigens inside of the capsid, to drive cell-mediated responses or
intracellular delivery of antigen, respectively (256).

Future considerations for ω-hydroxyemodin
Pharmacokinetics (PK) is the adsorbtion, distribution, metabolism, and excretion
(ADME) of a drug upon administration and it is important to understand for route of
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administration, dosing regimen, and toxicity. ω-Hydroxyemodin is a novel QS inhibitor,
and as such the PK has never been assessed and, additionally, understanding the PK of a
drug prior to determining its efficacy in vivo is of little use. In order to avoid common PK
pitfalls, ω-hydroxyemodin was coadministered subcutaneously with bacteria where it was
highly efficacious (Chapter 3). However, now that efficacy has been established
elucidating the PK parameters is essential. Although there are no PK studies for ωhydroxyemodin, inferences from the numerous studies on the parent compound emodin,
an herbal laxative, can inform strategies to enhance ω-hydroxyemodin PK. Importantly,
the major metabolite of emodin is ω-hydroxyemodin (Figure 4.2A), so these studies have
critical relevance (257, 258).
The first PK hurdle for ω-hydroxyemodin, gleaned from research with emodin, is
the very poor bioavailability due to rapid glucuronidation and excretion (257, 259, 260).
According to the emodin research, glucuronidation would occur on the oxygen of the 3hydroxy of ω-hydroxyemodin (Figure 4.2B). Changing the hydroxyl moiety so that
glucuronidation cannot occur would enhance bioavailibity. Bioisosteres, are chemical
moieties that share physical and/or chemical properties (261). Bioisosteres of the 3-OH
(e.g.: -Cl, -F or -CF3, Figure 4.2B1), could be assessed to identify molecules that are still
QS inhibitory but can no longer be glucuronidated (261).
The second PK issue to address is metabolic conversion of ω-hydroxyemodin to
genotoxic metabolites. Cytochrome P450 (CYP) oxidation generates several
hydroxylated metabolites of emodin, but 2-hydroxyemodin (Figure 4.2C) was shown to
be the direct-acting mutagen (257, 258). Additionally, CYP oxidation of emodin or ωhydroxyemodin was required for genotoxicity in S. typhimurium (258, 262, 263). The
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widespread use of emodin as a laxative, coupled with the potential genotoxicity,
prompted the National Toxicology Program (NTP) to assess emodin for toxicology and
carcinogenesis. There was no evidence of carcinogenic activity in a 2-year feed study for
male rats and female mice, and only equivocal evidence in female rats and male mice
exposed to up to ~200 mg/kg (264). Therefore, although toxic metabolites can be
generated in vivo, their effects may not be relevant at the doses required for agr inhibition
in vivo (~0.2 mg/kg) based on the NTP studies demonstrating only equivocal evidence at
~200 mg/kg. However, to mitigate the potential for toxic metabolite formation,
chlorination at position 2 of ω-hydroxyemodin should protect from CYP hydroxylation at
position 2 (Figure 4.2C1). Since 2-chlorinated ω-hydroxyemodin is available
commercially, it would be interesting to assess the effect of 2-chlorination on both QS
inhibition and genotoxicity.
Addressing these two key PK complications would greatly enhance the potential
for ω-hydroxyemodin to progress towards the clinic. Full PK studies addressing all of the
ADME properties for ω-hydroxyemodin specifically would also identify further PK
hurdles. Additionally, even if some of the PK complications cannot be overcome, ωhydroxyemodin may still be useful as a topical or locally administered therapeutic.
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Figure 4.2 – Metabolism pathways of emodin and ω-hydroxyemodin based on studies of emodin. (A) The major metabolite of
emodin is ω-hydroxyemodin via CYP hydroxylation of the 6-methyl. (B) Glucuronidation at 3-hydroxy of ω-hydroxyemodin, which
results in low bioavailibility. (B1) Protection of the 3-hydroxy of ω-hydroxyemodin with chlorine, fluorine or trifluormethyl might
prevent glucuronidation. (C) Hydroxylation of ω-hydroxyemodin resulting in the genotoxic 2-hydroxy metabolite. (C1) Protection of
the 2-carbon of ω-hydroxyemodin with chlorine might prevent hydroxylation and formation of genotoxic metabolite.
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Pharmacodynamics (PD) is the study of drug action or mechanism and is an
important consideration for reducing the side-effects of pharmaceuticals. Chapter 3
demonstrates that ω-hydroxyemodin binds AgrA and prevents activation of agr QS.
However, there are reports in the literature of emodin and ω-hydroxyemodin (also known
as citreorosein) having effects on eukaryotic targets (265–267). Specifically, ωhydroxyemodin and emodin inhibit inflammation induced via lipopolysaccharide (267) or
phorbal 12-myristate 13-acetate activation of mast cells (265, 266). Whether this effect is
specific for mast cells or is more generalizable remains to be seen. In Chapter 3 ωhydroxyemodin only reduced inflammation to levels seen with agr deletion strains. One
hypothesis based on these observations is that ω-hydroxyemodin may reduce virulence
induced inflammation and this may be a beneficial effect. However, to mitigate potential
off-target effects, combinatorial chemistry may be employed to enhance binding to AgrA
while limiting eukaryotic effects. In addition to enhancing the PD as described,
combinatorial chemistry products could also be assessed for enhancements to the PK.
The power of combinatorial chemistry to improve upon natural product
pharmacophores has been extensively demonstrated historically (122, 123, 125).
However, identification of the target binding site greatly enhances the power of
combinatorial chemistry (122). In Chapter 3 we demonstrated that ω-hydroxyemodin
binds to the C-terminal, DNA-binding fragment of AgrA potentially near the DNA
binding site (Figure 3.5B). Further refinement of the binding site would greatly enhance
combinatorial chemistry approaches. The identification of the binding site via
mutagenesis will most likely be difficult. Mutations near the proposed binding site which
would prevent ω-hydroxyemodin binding (implicating residues important for binding)
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could alter DNA-binding activity. This would require the more challenging SPR
technique, in contrast to the facile EMSA, for demonstration of binding. However, the
substantial benefit of binding site identification requires that these studies be attempted.
ω-Hydroxyemodin inhibited S. epidermidis quorum sensing, and because AgrA is
highly conserved amongst staphylococcal species, we hypothesize that ω-hydroxyemodin
might also inhibit QS in other species. As most of the staphylococci can cause human
disease, demonstrating ω-hydroxyemodin QS inhibition in other species would broaden
the clinical utility of ω-hydroxyemodin. Additionally, agr belongs to the LytTR family
of response regulators, and these regulators are utilized by many pathogens (203). It
would be interesting to determine if ω-hydroxyemodin can inhibit other members of the
LytTR family.

Clinical utility of QS inhibition
To date, there have been no clinical trials or FDA approved QS inhibitors,
although the data reported herein suggest their potential clinical utility. Specifically,
virulence factors regulated by the agr quorum sensing circuit are important for tissue
invasion leading to hematogenous dissemination (14, 15). Inhibitors of agr would
therefore be useful to prevent severe infection by preventing metastasis from primary to
distal infection sites. Specifically, inhibitors of QS would be efficacious as treatments to
limit skin infections. Active vaccination would benefit patient populations at risk of
developing skin infections, such as patients undergoing elective surgery, patients on
hemodialysis, diabetics, and other populations at high risk for infection (prisoners,
military personnel, and athletes). Likewise, prophylactic administration of ω-
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hydroxyemodin would benefit these same patients, but could also be used following
trauma when patients are more susceptible to infection because innate effectors that
inhibit quorum sensing are depleted (268). Additionally, agr activation occurs more than
once during infection (131), suggesting that post-infection therapeutic administration of
ω-hydroxyemodin may also be effective. Developing a biomarker to determine agr
activation status to predict the effectiveness of QS inhibitors would be a substantial
benefit in this regard. Additionally, for therapeutic use, although QS inhibitors are
designed not to have antibacterial activity and therefore would not prevent infection, their
ability to enhance immune-mediated bacterial clearance would promote resolution.
The anti-pathogenesis activity of QS inhibitors that leads to enhanced immune
function may even work as an adjunct to antibiotic therapy. Therapeutic treatment with
ω-hydroxyemodin and antibiotics may be an additive or synergistic combination due to
the immune enhancing effects on bacterial clearance coupled with the direct antibacterial
effects of the antibiotics. This may be specifically important for the β-lactams as the
mecA and mecR1 genes conferring resistance is positively agr-regulated in some strains
(44, 47). In fact, synergy was demonstrated between emodin and two β-lactams, although
emodin was attributed antibacterial activity in that study which makes interpretation of
agr inhibitory effects difficult (269). In addition, it is increasingly being recognized that
S. aureus may persist intracellularly in multiple cell types and that agr QS is important
for phagosomal survival and escape due to virulence factor production (231, 270, 271).
Because AgrA is cytosolic, ω-hydroxyemodin must be able to cross bacterial membranes.
An interesting question is, therefore, can ω-hydroxyemodin cross eukaryotic membranes
and prevent intracellular QS? This may be one of the mechanisms by which ω-
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hydroxyemodin enhances macrophage and neutrophil killing of S. aureus, although this
needs to be empirically determined. If proven correct, it would suggest that agr inhibition
aids infection resolution and prevents persistent intracellular survival. Finally, a cocktail
of specific S. aureus virulence inhibitors could also be thought of as a ‘narrow-spectrum’
strategy and one could also imagine the use of a ‘broad-spectrum’ cocktail against QS in
multiple pathogens. A broad-spectrum cocktail should target the antibiotic resistant
ESKAPE pathogens as quorum sensing is important in many of these pathogens
(Enterococcus faecium, S. aureus, Klebsiella pneumonia, Acinetobacter baumanii, P.
aeruginosa, and Enterobacter species). The ‘broad-spectrum’ therapy could be
administered empirically until the causative pathogen is known, and then narrowspectrum, specific therapy continued thereafter, as is currently done with antibiotics.
Demonstrating clinical uses beyond SSSI would greatly enrich the clinical impact
of agr inhibitors. However, the contribution of agr to other S. aureus disease states is not
well understood, so predictions of QS inhibitor effectiveness are not well guided.
However, there is evidence to suggest that agr is important for infection in pneumonia
(185), so assessing the benefit of QS inhibition in this model would be worthwhile. In
addition to other S. aureus disease states it would be interesting to determine the
effectiveness of QS inhibition in immunodeficiency. We hypothesize that QS inhibition
might compensate for immunodeficiencies. Animal models of several
immunodeficiencies are established which would allow testing of this hypothesis. It will
be important to determine under which immunodeficiencies agr inhibition can prove
efficacious in limiting infection. Finally, others have shown that neutralization of Hla
reduces the severity of recurrent infection (226). We predict that because ω-
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hydroxyemodin limits Hla production in vivo, that adaptive responses will be enhanced,
thus decreasing the severity of subsequent infection.
Inhibition of QS alone is not going to solve the antibiotic resistance crisis, but it is
another tool that can be used to fight resistance. Additionally, multiple pathogens utilize
quorum sensing suggesting inhibitors, or cocktails, would be beneficial. The work in
Chapter 2 and Chapter 3 demonstrate that inhibition of S. aureus QS using an active
vaccine or a natural product small molecule limits the severity of infection in vivo.
Several improvements can be made to either approach, enhancing their ability to move
towards clinical use. Finally, understanding the role of agr in other disease states would
broaden the clinical impact of agr inhibitors.
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APPENDIX A: Abbreviations
Ab – antibody
ABC Transporter – ATP-binding cassette transporter
ABTS - 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid
agrI-IV – accessory gene regulator type I-IV
ADAM10 – A disintegrin and metalloproteinase domain-containing protein 10
ADME – adsorbtion, distribution, metabolism, and excretion
AI – autoinducer
AIP1-4 – autoinducing peptide 1-4
Als3 – agglutinin-like sequence 3 protein
BSA – bovine serum albumin
BSI – blood stream infection
Cam – chloramphenicol
CAMP – Christie-Atkins-Munch-Peterson factor
CA-MRSA – community associated methicillin-resistant Staphylococcus aureus
Can – collagen binding protein
CDC – Centers for Disease Control and Prevention
cDNA – complementary DNA
CFU – colony forming unit
ClfA, B – clumping factor A, B
Coa - coagulase
CP5, 8 – capsule type 5, 8
Csa1A – conserved staphylococcal antigen 1A
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CYP – cytochrome P450
DNA – deoxyribonucleic acid
DMEM – Dulbecco's modified Eagle's medium
DMSO – dimethyl sulfoxide
DT – diphtheria toxin
DTaP – diphtheria, tetanus and pertussis vaccine
DTT – dithiothreitol
Eap – extracellular adherence protein
E. coli – Escherichia coli
EDTA – ethylenediaminetetraacetic acid
ELISA – enzyme-linked immunosorbent assay
EMSA – electrophoretic mobility shift assay
EpiP – epidermin leader peptide processing serine protease
Erm – erythromycin
EsxA, B – ess extracellular A, B
ESKAPE – E. faecium, S. aureus, K. pneumonia, A. baumanii, P. aeruginosa, and
Enterobacter species
exoA – exotoxin A
Fab – fragment antigen-binding
FAM – fluorescein amidite
FBS – fetal bovine serum
FDA – Food and Drug Administration
FhuD3 – ferrix hydroxamate-binding lipoprotein
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FnBPA, B – fibronection binding protein A, B
GFP – green fluorescent protein
Glc – PNAG fragment
Gt - goat
HA-MRSA – healthcare associated methicillin-resistant Staphylococcus aureus
HBSS – Hanks’ balanced salt solution
HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
H&E – hematoxylin and eosin stain
HiB – Haemophilus influenza B
Hla – alpha-hemolysin, also α-hemolysin
Hlb – beta-hemolysin, also β-hemolysin
Hld – delta-hemolysin, also δ-hemolysin
HPMC – hydroxypropylmethylcellulose
HRP – horseradish peroxidase
HSA – human serum albumin
HSL – homoserine lactone
IACUC – Institutional Animal Care and Use Committee
IgG – immunoglobulin G, also immunoglobulin gamma
IPTG – isopropyl-β-D-1-thiogalactopyranoside
IsdA, B – iron-regulated surface determinant A, B
KC – keratinocyte-derived chemokine
LB – Luria broth
LDH – lactate dehydrogenase
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LOS – length of stay
LTA – lipotechoic acid
LukF-PV, LukS-PV – Panton-Valentine leukocidin subunit F, S
LYST – lysosomal trafficking regulator
mAb – monoclonal antibody
MHCI, II – major histocompatibility complex I, II
MIC – minimum inhibitory concentration
MCF – mean channel fluorescence
MntC – manganese transport protein C
MOI – multiplicity of infection
mRNA – messenger ribonucleic acid
MRSA – methicillin-resistant Staphylococcus aureus
Ms - mouse
MSSA – methicillin-sensitive Staphylococcus aureus
MWCO – molecular weight cutoff
NADPH – nicotinamide adenine dinucleotide phosphate
NBT/BCIP - nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate
NIAID – National Institute of Allergy and Infectious Diseases
NIH – National Institute of Health
NLRP3 - NOD-like receptor family, pyrin domain containing 3
NTA – nitrilotriacetic acid
NTP – National Toxicology Program
OD – optical density
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OHM – ω-hydroxyemodin, also omega-hydroxyemodin and citreorosein
PAGE – polyacrylamide gel electrophoresis
pAb – polyclonal antibody
PBS – phosphate buffered saline
PCR – polymerase chain reaction
PD – pharmacodynamics
PK – pharmacokinetics
PMN – polymorphonuclear leukocyte
PMS – phenazine methosulfate
PNAG – poly-N-acetyl glucosamine
P. restrictum – Penicillium restrictum
PSM – phenol soluble modulin
qPCR – quantitative polymerase chain reaction
QS – quorum sensing
QSI – quorum sensing inhibitors
RAP – RNAIII activating protein
Rb – rabbit
Rh - rhesus
ROS – reactive oxygen species
Rot – repressor of toxins (transcription factor)
rRBC – rabbit red blood cell
RNA – ribonucleic acid
RPMI - Roswell Park Memorial Institute medium
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rt - rat
RT – room temperature
RT-PCR – reverse transcriptase polymerase chain reaction
SA - streptavidin
S. aureus – Staphylococcus aureus
SDS – sodium dodecyl sulfate
SdrD, E, G – serine-aspartate repeat D, E, G
SEB, SEC – staphylococcal enterotoxin B, C
SEl-X – staphylococcal enterotoxin-like X
sGFP – superfolder green fluorescent protein
SpA – Staphylococcus protein A
SPR – surface plasmon resonance
SSSI – skin and skin structure infection
STAT3 – signal transducer and activator of transcription 3
Std. Rx. – standard treatment
TAE – tris-acetate-EDTA buffer
TBST – tris-buffered saline
TCEP – tris(2-carboxyethyl)phosphine
TLR2 – toll-like receptor 2
tRNA – transfer ribonucleic acid
TSB – trypticase soy broth
TSST-1 – toxic shock syndrome toxin-1
TT – tetanus toxin
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UPLC – ultrahigh-performance liquid chromatography
USP – United States Pharmacopeia
USUHS – Uniformed Services University of Health Sciences
VISA – vancomycin-intermediate S. aureus
VLP – virus-like particle
VRSA – vancomycin-resistant S. aureus
vWbp – con Willebrand factor binding protein
WT – wild type
XTT – 2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide
YFP – yellow fluorescent protein
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